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Improving patient outcomes in chronic disease is of critical importance to the future 
of health care. Gout, affecting 4% of the US population, is a highly treatable chronic 
disease from which patients experience unnecessarily suboptimal outcomes. In this 
dissertation, I demonstrate how interrelated patient and provider factors affect patient 
outcomes in gout. First, I describe how only 14% of gout patients know their serum urate 
(SU) goal for urate lowering therapy (ULT) despite otherwise being knowledgeable about 
gout and its treatment. I then demonstrate the importance of multiple patient and 
provider factors in achieving SU goal. Specifically, I demonstrate that ULT medication 
adherence, ULT dose escalation and a high ULT starting dose are associated with SU 
goal attainment. However, I show that a high starting dose is also associated with worse 
SU goal attainment through its negative impact on medication adherence. These 
findings demonstrate not only the importance of patient and provider behaviors in 
achieving optimal outcomes, but also their interrelated nature. Finally, I report that there 
is no evidence from a large national study that ULT dose escalation reduces mortality 
among gout patients. In further analysis, I demonstrate that the lack of evidence could 
be due to inadequate final ULT doses observed even among patients receiving dose 
escalation. Importantly, the patient and provider factors I identify in this work are all 
modifiable. Future interventions should address the broad care context outlined in the 
Chronic Care Model to target these interrelated, modifiable factors and achieve optimal 
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Chapter 1: Introduction 
1.1 Chronic Illness and Care 
Chronic illness has become the single greatest contributor to decreases in 
individuals’ quality of life and has also begun to drive health care cost.1-3 In the United 
States (US), approximately half of all adults have one or more chronic illnesses and half 
of those have at least 2 chronic illnesses.4 Chronic illnesses such as asthma, diabetes 
and gout can lead to substantial activity limitations and loss of quality of life.5-7 Care for 
patients with one or more chronic illnesses now accounts for over 85% of health care 
spending today.3 Yet, despite the ubiquitous and increasing impact of chronic illness, 
patients and the health care system struggle to achieve optimal, but attainable, 
outcomes.2,8 
In 1996, Wagner et al. created one of the first models for understanding and 
improving chronic illness care: the Chronic Care Model (CCM).9 The model was 
developed in response to growing recognition that patients, health care providers and 
the health care system are too often ill-prepared to address chronic care needs. Patients 
with one or more chronic illnesses must often engage in more extensive and long-lasting 
self-management activities than patients with acute illnesses.10 Yet, many patients 
burdened by chronic illness are not aware of or prepared for the self-management 
necessary to achieve desired results.11,12 Similarly, there is evidence that health care 
providers deviate from the best practices necessary to support patients with chronic 
illness in achieving optimal outcomes. More broadly, there is evidence from a systematic 
review of health systems’ chronic care improvement initiatives that broader contextual 
factors affect chronic illness care outcomes.13 Wagner and colleagues assembled this 
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evidence into the CCM in order to depict relevant domains that need to be targeted to 
improve chronic illness care and outcomes. 
Over time, the CCM framework (Figure 1) developed to reflect how chronic care 
occurs in 3 overlapping environments: the community, the health care system and the 
health care provider’s organization.14 Within these environments, CCM identifies 6 areas 
where targeted efforts affect outcomes: community resources and policies, self-
management support, delivery system design, decision support, clinical information 
systems and the organization of health care. Each of these areas contributes to patient 
outcomes in unique ways, but ultimately facilitate “an informed, activated patient 
interacting with a prepared, proactive practice team” to produce “high-quality, satisfying 
encounters and improved outcomes.”14 
In chronic care, CCM recognizes that patients become their own primary caregiver.10 
They are, therefore, required to have a broad range of self-management skills in 
problem solving and resource utilization.12 Patients with these skills tend to achieve 
better outcomes.15,16 Health care providers, by contrast, provide medical insight, 
encourage development of problem-solving skills, and help access resources over 
time.10 If health care providers are well prepared, knowledgeable, and proactive about 
specific chronic care needs, patients are more likely to experience improved outcomes. 
The model suggests that patients and providers together, through productive interactions 
related to their roles, may achieve optimal care outcomes.17 
Using CCM as a framework, barriers to optimal outcomes for specific diseases can 
be better identified and understood. In the following section, I use the CCM as a 
framework for understanding evidence of suboptimal outcomes in gout with particular 




Figure 1  Chronic Care Model 
The Chronic Care Model (CCM) places emphasis on productive interactions between an informed, activated patient and a prepared, proactive health care team. 
These interactions occur within the context of 3 overlapping environments: the community, health systems and provider organizations. Within these environments, 
the model identifies 6 essential areas that together affect how patients and providers interact to improve outcomes in chronic disease care. Adapted with 
permission from work by Wagner and colleagues at the MacColl Center for Health Care Innovation.18 Copyright 1996-2015 The American College of Physicians.
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1.2 Gout and Gout Management 
Gout is the most common inflammatory arthritis in the US with a prevalence that 
has increased in recent decades to nearly 4%.19,20 Resulting from sustained 
hyperuricemia, gout can have a considerable, negative impact on individuals’ quality of 
life leading to increased work absenteeism,21 disability,22-24 and health care utilization.25-
27 Furthermore, gout and hyperuricemia may be related to an increased risk of 
mortality.28-31 Yet, despite the substantial prevalence and health impact of gout, and the 
availability of highly effective management strategies, suboptimal patient outcomes 
remain all too common.32,33 
As with any chronic disease, achievable outcomes in gout are partially a function 
of the disease process itself as well as available treatments. Gout has a well-defined 
disease pathogenesis.34 It is characterized by intermittent, extremely painful bouts of 
arthritis called attacks or flares.35 These attacks are induced by the presence of 
monosodium urate (MSU) crystals in synovial joints and surrounding tissues secondary 
to persistent hyperuricemia. Attacks typically last 5 to 12 days without treatment36 and 
are followed by periods of disease quiescence, often termed intercritical gout.35 
Untreated, the attack frequency increases alongside the body’s total MSU crystal burden 
until a persistent arthritis develops, a severe form of gout characterized by the 
subcutaneous deposition of MSU termed tophi.34 Treated properly, however, a diagnosis 
of gout does not need to result in intractable future gout attacks. 
Medical treatment of gout is commonly divided into two parts: short-term alleviation 
of the pain and inflammation from the attack37 and long-term urate lowering therapy 
(ULT) to reduce MSU crystal burden.38 For short-term therapy targeting attacks, the 
most common therapies used are anti-inflammatory doses of non-steroidal anti-
inflammatory drugs (NSAIDs), colchicine, and/or glucocorticoids. For long-term therapy, 
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xanthine oxidase inhibitors (XOI) are considered first-line therapy and are the most 
commonly prescribed ULT.38 Numerous studies have shown that patients on XOIs, 
especially those achieving and maintaining a serum urate (SU) concentration < 6.0 
mg/dl,39 experience reduced tophi size, frequency of flares, and pain.40-42 The reduction 
in MSU crystals resulting from ULT and cessation of gout attacks can be so dramatic 
after long-term maintenance below SU goal that “cure” is not an uncommon outcome 
described in the literature.43,44 However, most patients never achieve SU goal and are 
thus likely continue to experience gout attacks.32 
The CCM suggests a framework for achieving optimal outcomes such as SU goal 
and elimination of future gout attacks.14 For a chronic disease like gout, the model 
emphasizes the role of a proactive health care team and an informed, active patient. The 
model then places the provider and patient in a broader context composed of 6 essential 
areas.  While I return in Chapter 5 to the importance of these 6 areas for the future of 
gout care, this dissertation first investigates the role of provider and patient behaviors in 
achieving optimal outcomes.  
From the provider perspective, there is myriad evidence demonstrating that gout 
care is suboptimal. For instance, health care providers may perform suboptimally 
according to both quality indicators and safe prescribing benchmarks.45-48 Recognition of 
these potential issues, in part, prompted the development of evidence- and consensus 
based guidelines by multiple international groups.37,38,49,50 Since publication of those 
guidelines, studies have consistently demonstrated that provider practices remain 
suboptimal.32,33,48,51 For instance, the 2012 American College of Rheumatology (ACR) 
gout management guidelines suggest that health care providers start gout patients on a 
low ULT dose (e.g. allopurinol ≤ 100 mg/day) followed by gradual dose escalation until 
SU is < 6.0 mg/dl.38 Yet, only one in four patients have SU assessments within 6 months 
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of ULT initiation and less than one-third ever undergo ULT dose escalation.32 While 
there have been widespread reports of suboptimal care, there is currently limited 
knowledge regarding which provider behaviors affect attainment of optimal outcomes in 
gout such as SU goal < 6.0 mg/dl.32,52 
From the patient perspective, long-term self-management of gout consists 
primarily of understanding the disease and its treatment, properly taking ULT, and 
avoiding life-style risk factors.38Like providers, there is evidence that patients struggle in 
their chronic care role. There are qualitative reports that patients lack understanding of 
gout and its treatment.53-55 Medication nonadherence has been well described in gout 
with approximately 6 out of every 10 patients being considered nonadherent to 
prescribed ULT.32,56 However, few studies connect any specific patient behaviors, 
including ULT adherence to achieving the optimal outcome of SU goal attainment in 
gout.32,52 Further work is needed to demonstrate that this association is independent of 
the many other healthful behaviors in which adherent patients often simultaneously 
engage.57 
Taken together, there is burgeoning evidence that patient and provider behaviors 
are suboptimal in gout, but limited evidence connecting these behaviors to important 
outcomes. Furthermore, no studies have investigated how these behaviors may relate 
through potential causal pathways.  Further work demonstrating the interrelation of 
patient and provider factors with outcomes could inform future interventions using the 
CCM framework to improve outcomes in gout. 
1.3 Dissertation Objectives and Contributions 
The objective of this dissertation is to develop a model of modifiable patient and 
provider factors associated with optimal outcomes in gout. In Chapter 2, I describe 
patients’ gout-specific knowledge, including a lack of knowledge regarding an important 
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therapeutic goal, and the opportunity that this gap in knowledge represents for a goal-
oriented care approach. In Chapter 3, I develop a more comprehensive model to test the 
hypothesis that certain interrelated patient and provider factors are associated with SU 
goal attainment, including some factors that appear to indirectly impact this outcome 
through medication adherence. In Chapter 4, I demonstrate the potential importance of 
these patient and provider behaviors by testing the hypothesis that one provider factor, 
appropriate ULT dose escalation, is associated with decreased mortality among gout 
patients. Finally, in Chapter 5, I discuss how the work presented in this dissertation 
contributes to our understanding of how to improve gout care within the context provided 
by the CCM framework. 
Chapter 2: Target Serum Urate: Do Gout Patients 
Know Their Goal? 
2.1 Background 
Self-management is recognized as an important driver of outcomes in chronic 
diseases, including gout. Treatment goals provide focus for self-management activities 
and promote integration of valuable feedback for patients regarding their progress.58,59 A 
treat-to-target serum urate (SU) strategy for gout patients with an indication for urate 
lowering therapy (ULT) has been widely endorsed as a means of optimizing clinical 
outcomes. Achievement of a SU < 6 mg/dL has been associated with improved 
outcomes, including reductions in gout flare frequency and tophi.39-42,60,61 Thus, multiple 
international guidelines support the adoption of such a treatment target.38,49,50,62 The 
target is intended to guide health care providers’ care, but it also represents a critical 
domain of patients’ gout-specific knowledge. The European League Against 
Rheumatism (EULAR) reported “that [patient] education on gout and its treatment 
improves outcome[s].”49  The recently published American College of Rheumatology 
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(ACR) guidelines were more explicit in recommending that patients understand the role 
of uric acid as “the key long-term treatment target.”38 
Although substantial attention in gout has been given to suboptimal adherence to 
quality of care indicators among providers45-47 and low SU goal attainment among 
patients,32,48 it is largely unknown to what extent patients understand gout and their 
treatment. Patients report that they are concerned, but uninformed about whether or not 
ULT triggers gout attacks,55 a well-recognized event complicating such treatment. Other 
patients lack familiarity with ULT as a treatment option and do not appear to understand 
its role in gout management.54 Furthermore, patients who believe they have little control 
over their gout or believe that treatment does not help control their gout experience 
worse musculoskeletal disability over time.53 The low level of confidence and disease 
knowledge reported by patients stands in stark contrast to the robust evidence 
supporting the efficacy of ULT.40-42 
Many gout educational materials (>50%) fail to address SU goal attainment.63 It 
remains largely unknown whether patients understand the role that uric acid plays in 
gout and the importance of SU goal attainment in chronic disease management.  The 
objective of the present study was to examine gout patients’ knowledge of their 
condition, including the central role of achieving and maintaining SU goal with the use of 
ULT.  Furthermore, I examined, for the first time, factors associated with SU goal 
knowledge and whether having this knowledge is associated with select health 
outcomes. 
2.2 Methods 
Design and Setting 
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This was a cross-sectional study to determine levels of gout-specific knowledge and 
factors associated with gout-specific knowledge among a population of gout patients at a 
single Midwestern Veterans Affairs (VA) medical center. The study was approved by the 
local VA Institutional Review Board. 
Sample and Procedures 
Patients were 19 years or older with at least one gout International Classification of 
Diseases (ICD)-9 code (274.XX), excluding gouty nephropathy (274.19, 274.10), and 
filled at least one allopurinol prescription between August 1, 2011 and July 31, 2012 
(“enrollment allopurinol”). Most patients’ first allopurinol was prescribed prior to the 
enrollment allopurinol meaning that a majority of identified patients were prevalent 
allopurinol users. A total of 1,553 patients met inclusion criteria (Figure 2). Patients were 
excluded if they were deceased or had one of four conditions, each recognized as a 
potential alternative indication for allopurinol as recorded by ICD-9 codes: a history of 
hematologic malignancy, tumor lysis syndrome, stage 5 chronic kidney disease (CKD) or 
nephrolithiasis.  
A total of 1,437 patients, representing all remaining eligible patients, were mailed a 
recruitment letter and questionnaire in February 2014. A repeat mailing occurred 6 
weeks following the initial mailing for non-responders with responses accepted until May 
2014 similar to the Dillman method.64 The questionnaire included 43 questions used to 
collect socio-demographics, patient activation, health outcomes, gout knowledge, and 
patients’ treatment plan confidence.  
Linking responses to administrative data, I reapplied exclusion criteria using 
laboratory proxies for tumor lysis syndrome (SU > 6 standard deviations above the 
mean) and CKD stage 5 (estimated glomerular filtration rate (GFR) < 15 ml/min). I 
required patients to have a pre-enrollment period of at least 6 months of observation with 
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no allopurinol prescription prior to their first ever allopurinol prescription on record. To 
determine the 6 month period, I assessed the patient’s first observable event in the VA 
defined as the first clinic visit or pharmacy prescription fill. If the patients’ first observable 
event was greater than 6 months prior to the first allopurinol fill, then they were included 
in the study. This reduced potential misclassification of allopurinol starting dose and 
dose escalation as well as anti-inflammatory prophylaxis. Application of these final 
criteria excluded 274 individuals who had returned their questionnaires. 
Questionnaire. The questionnaire was composed of 43 questions, including the 
following: sociodemographics, a modified version of a gout-specific knowledge 
questionnaire,65,66 the Patient Activation Measure (PAMTM),67,68 and self-reported health 
outcomes. The gout-specific knowledge section was adapted from a longer 
questionnaire resulting in 6 multiple-choice questions as summarized in Table 1. All 
questions had 1 correct answer among 5 options with “Don’t know” as a possible option 
for each question. Missing answers were coded as “Don’t know.” The gout-specific 
knowledge section of the questionnaire had an excellent response rate with only 0.8 to 
2.9% missing data for any question and 98.4% of respondents missing responses for 1 
or fewer questions out of 6. 
The PAMTM is used to quantify a patient’s engagement in their own care regardless 
of the specific condition they have. It is designed to assess a person’s self-perceived 
knowledge, skills and confidence related to managing their health and health care on a 
unidimensional, developmental scale from the least activated at 0 to the most activated 
at 100.67,68 The most recent version includes 13 questions with strong psychometric 
properties that can categorize patients into 4 levels (1-4), where 1 is least activated and 
4 is most activated.68 Patients in level 1 tend to be passive partners in their own health 
care and view their health provider as being in charge, whereas patients at level 4 
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actively adopt healthful behaviors and see themselves as their own primary health 
advocate. The PAM was scored according to Insignia Health recommendations.69 
For self-reported health outcomes, patients were asked to report the number of gout 
flares they had in the past 6 months and rate their current overall health and gout-
specific health on a visual analog scale (0 to 10 cm). For health-related quality of life, all 
patients completed the EQ-5D-5L.70 
Electronic Records. Clinical VA laboratory data were a source of many study 
measures including the determination of whether patients ever achieved SU goal after 
ULT initiation (< 6.0 mg/dL). ICD-9 codes were used to determine each patient’s 
comorbidity burden as measured by the Rheumatic Disease Comorbidity Index 
(RDCI).71,72 Each patient’s most recent GFR (ml/min/1.73 m2) and body mass index 
(BMI, kg/m2) were abstracted. The proportion of days covered (PDC) was used to 
determine medication adherence from prescription dispensing data. The PDC is defined 
as the number of days the patient has medication available out of the total days of 
observation (days with medication available/days of observation) after adjusting for early 
refills and truncating at the end of observation. It is endorsed by the Pharmacy Quality 
Alliance as the preferred method for quantifying medication adherence using pharmacy 
claims data.73 For this study, the PDC was calculated during a fixed, 360-day period 
initiating on the day of the patient’s first allopurinol prescription after August 1, 2011. 
This provided a fixed time period of sufficient length for medication adherence 
observation nearest the time of questionnaire completion. National Provider Identifier 
and Drug Enforcement Administration numbers as well as VA clinic codes were used to 
determine providers and clinical specialties associated with each gout diagnosis and 
allopurinol prescription. Treatment duration was defined as the number of years between 
first allopurinol prescription and final on record. Finally, dose escalation was defined as 
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an increase in the dose of allopurinol from the first dose in the record to the final dose 
without regard to intervening doses, also consistent with previous literature.32  
Statistical Analysis. Demographic and questionnaire data were analyzed using 
descriptive statistics. Internal consistency for the gout-specific knowledge questions was 
assessed using Cronbach’s Alpha. Chi-squared, Wilcoxon rank-sum and t-tests were 
used to determine factors associated with SU goal knowledge. Multivariable logistic 
regression with backwards stepwise selection, beginning with factors significant at an 
alpha ≤ 0.2 level in bivariate analyses, was used to determine independent associations 
with SU goal knowledge. Two sensitivity analyses were done requiring patients to have 2 
or more gout diagnostic codes separated by 30 days or more (n = 69 excluded) and 
requiring 12 or more months of prior observation (n = 54 excluded). Given the limited 
number of patients demonstrating this knowledge and the number of possible health 
outcomes examined, associations of SU goal knowledge with gout outcomes were 
examined in unadjusted exploratory analyses without statistical correction for multiple 
comparisons. Considering the number of SU tests following the first ULT on record, the 
count was modeled using a generalized linear model assuming a negative binomial 
distribution to account for over-dispersion and a log link. All analyses were done in SAS 





Figure 2  Study Flow Diagram 
Study personnel began with a list of 1553 patients already excluding those patients with ICD-9 codes for 
tumor lysis syndrome, stage 5 chronic kidney disease (CKD), gouty nephropathy or nephrolithiasis. 
Separate lists of recently deceased patients (n = 54) and patients with a history of cancer (n = 28) who met 
study inclusion criteria were provided, but subsequently excluded. Prior to the first questionnaire mailing, 34 
patients elected to opt out upon receiving the recruitment letter. From the mailing, 100 more opted out, were 
learned to be deceased or had no forwarding address. Overall, the questionnaire had a 62% response rate 
(886/1437). Using laboratory proxies, the tumor lysis syndrome and CKD stage 5 exclusion criteria were 
reapplied. Additionally, a 6-month allopurinol-free pre-enrollment period of observation was required. The 




Of the original 1,437 patients mailed a questionnaire, 886 (62%) returned their 
questionnaires. After exclusion criteria were reapplied, the overall cohort size was 612 
patients whose primary indication for allopurinol was gout and who had at least 6 months 
of prior observation before receiving their first allopurinol prescription. Questionnaire 
responders were similar to non-responders in age (72.1 years vs. 72.8 years, p = 0.36), 
proportion that were male (98.2% vs. 99.2%, p=0.15), BMI (32.4 kg/m2 vs. 32.0 kg/m2, p 
= 0.41), comorbidity burden (RDCI 2.8 vs. 3.0, p=0.12), treatment duration (5.9 years vs. 
6.2 years, p = 0.59) and GFR (65.5 mL/min vs. 65.5 mL/min, p = 0.99) (Table 2). In 
contrast, questionnaire responders were more likely than non-responders to have 
received their first prescription for allopurinol in a rheumatology office vs. primary care or 
other (6.9% vs. 2.0%, p < 0.001) and were more adherent to allopurinol (PDC median 
0.94 vs. 0.91, p = 0.005). Questionnaire responders were also more likely than non-
responders to have had a SU level checked within the first 2 years after ULT initiation 
(66.0% vs. 52.9%, p < 0.001).  
Among questionnaire responders, the mean age of first gout attack was 51.6 years, 
a majority self-reported Caucasian race (89%), and had at least a high school graduate 
level of education (89%). Using allopurinol prescription fill data, I determined that 
questionnaire responders received care from a large number of health care providers (n 
= 405), but that 49 providers (12%) were responsible for 74% of the filled allopurinol 
prescriptions. A similar distribution was observed when using ICD-9 codes. Providers 
from two clinics accounted for 91% of prescription fills (89% from primary care and 2% 
from rheumatology). Rheumatologists were involved at any time in prescribing 
allopurinol for 74 (12%) of the 612 gout patients. 
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The proportion of gout patients answering correctly was high for all knowledge 
questions except SU goal (Table 1). For the 5 questions other than SU goal, 72% of 
respondents answered correctly on 4 or more questions. By comparison, only 14% knew 
their SU goal. The vast majority (78%) of responders chose “Don’t know” for the SU goal 
question compared to only 6 to 35% choosing “Don’t know” for any other question. The 
six-question gout-specific knowledge section had acceptable internal consistency (0.61) 
with the SU goal question and was slightly improved without it (0.64). 
A variety of demographics, baseline health behaviors and health process factors 
were associated with SU goal knowledge in bivariate and logistic regression analyses 
(Table 3). In unadjusted analyses, patients demonstrating SU goal knowledge were 
younger, had a lower comorbidity burden, were more activated as measured by the 
PAM, were more likely to get all other gout-specific knowledge questions correct, be 
treated by a rheumatologist and have their ULT dose escalated during observation. In 
multivariable logistic regression, patients with rheumatologists as the initial prescriber 
had 3.0 times the odds of knowing their SU goal as patients with other types of providers 
(95% CI 1.4 to 6.2). Patients with 1-point higher RDCI had 17% lower odds of knowing 
their SU goal (95% CI 0.70 to 0.98). As might be expected, patients who knew the other 
5 gout-specific questions had 2.1 times the odds of knowing their SU goal compared to 
patients who correctly answered 4 or fewer questions (95% CI 1.3 to 3.4). Because 
some patients may interact with rheumatologists later in their care, I also considered 
whether patients had ever been prescribed allopurinol by a rheumatologist. The adjusted 
odds ratio for this association increased to 3.8 (95% CI 2.1-6.9) while the estimates for 
RDCI and High Gout Knowledge remained stable (data not shown).  
In exploratory analysis considering major health outcomes (Table 4), SU goal 
knowledge was not associated with the EQ-5D-5L health utility index (p = 0.45), gout 
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specific health (p = 0.72) or SU goal attainment < 6.0 mg/dL (p = 0.44). However, gout 
patients with SU goal knowledge reported slightly better overall health on an 11-point 
VAS compared to patients without that knowledge (8 vs. 7, p = 0.04). Additionally, there 
was a trend, though not statistically significant, toward patients with SU goal knowledge 
having more attacks within the past 6 months. SU goal knowledge was associated with 
an increase in SU tests during 1- and 2-year periods following ULT initiation after 
controlling for whether a rheumatologist was the initial prescriber. During the first year of 
therapy, SU goal knowledge was associated with 45% (95% CI 1.10 to 1.92) more SU 
laboratory tests. Extending to a 2-year follow-up, SU goal knowledge was associated 
with 56% (95% CI 1.23 to 1.97) more SU laboratory tests.  
In sensitivity analyses, limited to patients with at least two diagnostic gout codes or 
with at least 12 months of prior observation, similar results were observed with respect 
to the proportion of patients demonstrating SU goal knowledge and its associations with 
potential predictors and health outcomes (data not shown). 
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Table 1  Gout-specific Knowledge Questionnaire 
 n=612 (%) 
1. What is the ideal blood uric acid level to aim for when treating 
gout? Blood uric acid levels are measured in mg/dL. 
 
a. Lower than 10 14 (2.3%) 
b. Lower than 8 26 (4.3%) 
c. Lower than 6 83 (13.6%) 
d. Lower than 2 14 (2.3%) 
e. Don’t know 475 (77.6%) 
2. What causes gout?  
a. Too little calcium 2 (0.3%) 
b. Too much uric acid 520 (85.0%) 
c. An infection 3 (0.5%) 
d. Diabetes 5 (0.8%) 
e. Don’t know 82 (13.4%) 
3. What causes gout attacks?  
a. Infection in the joint 43 (7.0%) 
b. Allopurinol in the blood 6 (1.0%) 
c. Crystals in the joints 411 (67.2%) 
d. Calcium in the blood 5 (0.8%) 
e. Don’t know 147 (24.0%) 
4. How do you know if you have a gout attack?  
a. You have a painful swollen joint 566 (92.5%) 
b. You have a change in your blood tests 3 (0.5%) 
c. Your skin gets red and itchy 9 (1.5%) 
d. You have a lump in your ear 0 (0.0%) 
e. Don’t know 34 (5.6%) 
5. Lowering your uric acid can help prevent future gout attacks. 
Which of these drugs can lower your blood uric acid? 
 
a. Allopurinol 489 (79.9%) 
b. NSAIDs like ibuprofen, naproxen and indomethacin 11 (1.8%) 
c. Prednisone 9 (1.5%) 
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d. Colchicine 34 (5.6%) 
e. Don’t know 69 (11.3%) 
6. If you are taking a drug to lower your blood uric acid levels, how 
long do you need to take this drug? 
 
a. One month 8 (1.3%) 
b. One year 5 (0.8%) 
c. Two years 5 (0.8%) 
d. Forever 380 (62.1%) 
e. Don’t know 214 (35.0%) 
* Patients were asked to only mark one option per question. Bold answers represent the correct answer. 
For the “Primary Attack Symptoms” question, a number of patients recorded multiple symptoms and were 
given credit if they included the most accurate answer in bold above. For all other questions, multiple 




Table 2  Demographics of Questionnaire Responders and Non-responders 
 
Responders 
(n = 612) 
Non-responders 
(n = 501) 
P 
Demographics 
   
Age, years 72.1 (10.7) 72.8 (13.1) 0.36 
Male 601 (98.2%) 497 (99.2%) 0.15 
Caucasian 536 (89.0%)  - 
Married 325 (54.4%)  - 
≥ High School Graduate 536 (88.9%)  - 
Baseline Health    
BMI, kg/m2 32.4 (6.3) 32.0 (6.8) 0.41 
RDCI 2.83 (1.48) 2.97 (1.55) 0.12 
GFR, ml/min/1.73 m2 65.5 (22.3) 65.5 (25.5) 0.99 
Age at First Gout Attack, years 51.6 (16.2)  - 
Health Behavior    
PDC 0.94 [0.77- 0.99] 0.91 [0.67-0.99] 0.005 
Health Processes of Care    
Rheumatologist Prescriber 42 (6.9%) 10 (2.0%) <0.001 
Received Dose Escalation 206 (33.7%) 155 (30.9%) 0.33 
SU test within 1 year 298 (48.7%) 209 (41.7%) 0.02 
SU test within 2 years 404 (66.0%) 265 (52.9%) <0.001 
Values in bivariate analysis are frequency (%), mean (± SD) or median [Interquartile range]. 
Percentages represent analysis in non-missing data. Body mass index (BMI); Rheumatic Disease 
Comorbidity Index (RDCI); glomerular filtration rate (GFR); proportion of days covered (PDC); Patient 
Activation Measure (PAM); serum urate (SU); Confidence Interval (CI); race/ethnicity, marital status, 








Table 3  Association of Patient Characteristics with Target Serum Urate Knowledge 
 Unadjusted  Multivariable Adjusted (n=612) 
 Knew SU 
goal 
(n = 83) 
Did not know 
SU goal 
(n = 529) 
P  Odds Ratio (95% CI) P 
Demographics 
      
Age, years 68.7 (10.2) 72.7 (10.6) <0.001    
Male  82 (99%) 519 (98%) 0.66    
Non-Hispanic Caucasian†  73 (89%) 463 (89%) 0.99    
Married†  46 (57%) 279 (54%) 0.64    
≥ High school graduate†  75 (93%) 461 (88%) 0.25    
Baseline Health       
BMI, kg/m2 33.1 (5.3) 32.2 (6.4) 0.17    
RDCI 2.46 (1.52) 2.88 (1.47) 0.015  0.83 (0.70 to 0.98) 0.03 
GFR, ml/min/1.73 m2 67.8 (23.1) 65.2 (22.1) 0.32    
Age at first gout attack 48.6 (16.2) 52.1 (16.2) 0.08    
Health Behaviors       
PDC 0.92  
[0.74 - 0.99] 
0.95  
[0.77 - 1.00] 
0.18    
PAM 62.1 (11.6) 58.6 (11.3) 0.012    
High Gout Knowledge‡ 46 (55%) 193 (36%) 0.001  2.1 (1.3 to 3.4) 0.002 
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 Unadjusted  Multivariable Adjusted (n=612) 
 Knew SU 
goal 
(n = 83) 
Did not know 
SU goal 
(n = 529) 
P  Odds Ratio (95% CI) P 
Health Care Process       
Rheumatologist Prescriber 12 (14%) 30 (6%) 0.008  3.0 (1.4 to 6.2) 0.004 
Received Dose Escalation 33 (40%) 154 (29%) 0.05    
Values in unadjusted analysis are frequency (%), mean (± SD) or median [Interquartile range]. Percentages represent analysis in non-missing 
data. 
† Variables were dichotomized for analysis: non-Hispanic Caucasian vs. other, currently married vs. not married and high school graduate vs. less 
than high school graduate.  
‡ High Gout Knowledge was defined as answering all 5 of gout-specific questions correctly when excluding the SU goal question. Body mass index 
(BMI); Rheumatic Disease Comorbidity Index (RDCI); Glomerular filtration rate (GFR); Proportion of days covered (PDC); Patient Activation 
Measure (PAM); Confidence Interval (CI). 
22 
 
Table 4  Health Outcomes by SU Goal Knowledge 
 Knew SU goal 
(n = 83) 
Did not know SU 
goal 
(n = 529) 
P 
EQ-5D-5L 0.79 [0.69 to 0.86] 0.78 [0.66 to 0.83] 0.45 
Overall Health, 0 to 11 8 [6 to 9] 7 [5 to 8] 0.04 
Gout Specific Health, 0 to 11 8 [7 to 9] 8 [6 to 10] 0.72 
SU Goal Attainment < 6.0 mg/dl 60 (75%) 319 (71%) 0.44 
Gout Attacks in prior 6 months   0.054 
0 attacks 39 (49%) 305 (59%)  
1 attack 12 (15%) 72 (14%)  
> 1 attack 28 (35%) 140 (27%)  





This large population of gout patients demonstrated a significant lack of knowledge 
about an internationally endorsed treatment target in gout. Only 14% of patients 
responded with the correct SU goal of < 6.0 mg/dL and nearly 80% specifically endorsed 
a lack of knowledge about their treatment goal. It is now widely accepted that patients 
should be actively engaged in decision-making regarding their treatment. International 
guidelines specifically recommend patient education on SU goal and the importance of 
uric acid as a treatment target.38,49 This study confirms preliminary evidence from a small 
questionnaire development study, which showed that only 5 out of 39 U.S. gout patients 
at a single rheumatology clinic knew their SU goal.65 The current study is the first to 
show this in a large population of gout patients seen by both rheumatologists and non-
rheumatologists, including primary care providers. 
Patient knowledge of disease and treatment is an important part of a complex array 
of psychosocial factors that have been shown to impact health outcomes. While data 
supporting the need for specific knowledge is limited, goal setting and goal pursuit are 
hypothesized to be integral aspects of persuading and motivating patients to adopt 
positive health behaviors.58,59 For example, collaborative goal setting has been 
associated with improved outcomes in other chronic health conditions, including 
diabetes and hypertension, where treat-to-target approaches have garnered greater 
support.74,75 The Chronic Care Model (CCM) suggests that optimal outcomes may be 
achieved by knowledgeable patients actively engaged in collaborative care with a 
prepared, proactive medical team.9,18,76 In support of this model for gout, a proof-of-
concept study showed that when health care providers educate and engage gout 
patients in order to promote positive self-management behaviors, the overwhelming 
majority (>90%) achieve SU goal.77 Importantly, patient education specific to SU goal 
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attainment as part of a treat-to-target approach was a focus of this successful pilot 
intervention. The current study is the first to show that goal setting with patients is not 
likely to be a widespread or effectively integrated concept in gout treatment. Even 
among gout patients most likely to demonstrate SU goal knowledge, those with 1 or 
more attacks in the past 6 months treated initially by a rheumatologist, less than 40% 
knew their SU goal. 
Prospective studies in hypertension and diabetes have shown that communication 
about treatment goals within a collaborative treatment setting is associated with 
improved outcomes.74,75 In the current study, SU goal knowledge was independently 
associated with an increase in the number of SU measurements during the first 2 years 
following ULT initiation. This is important because SU measurement is a prerequisite for 
proper ULT dose titration leading to SU goal attainment.38 In other studies, up to 60% of 
patients do not receive a SU measurement within the first 2 years of observation 
following prescription of ULT.48 Although the analyses were limited by the relatively small 
proportion of subjects demonstrating knowledge (n = 83), SU goal knowledge was 
associated with slightly better self-reported general health. This same knowledge 
demonstrated no association with other distal health outcomes, including health related 
quality of life measured using the EQ-5D-5L. There was a trend, albeit not reaching 
statistical significance, towards SU goal knowledge being associated with increased gout 
flares. This result should be interpreted with caution, however, as neither the direction 
nor reasons for this association can be determined. For instance, it is possible that 
greater knowledge of gout could lead to increased awareness and reporting of flares. 
Alternatively, it is possible that an increased number of flares leads to greater pursuit of 
detailed gout-specific knowledge or receipt of a rheumatology referral where their SU 
goal may be more likely discussed.  
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The results of this study should be taken in the context of the population studied and 
its cross-sectional design. The cross-sectional design precluded my ability to determine 
causation. The questionnaire design limited my ability to determine the patients’ reasons 
for not knowing SU goal, underscoring the potential for this topic as a promising area of 
future research. While the majority of the questionnaire required only limited recall, there 
is a potential for recall bias with 6-month flares questions. However, self-report is 
increasingly accepted as the critical patient-centered outcome in gout. Initial eligibility 
was determined by allopurinol receipt during a recent pre-defined 1-year time period. 
This led to a high proportion of prevalent allopurinol users relative to incident users. 
Furthermore, included patients were by definition willing to respond to a questionnaire. 
These two factors likely led to a more engaged and healthy study population as was 
evidenced in part by the comparison between questionnaire responders and non-
responders in Table 2. Importantly, this suggests that the estimate of SU goal 
knowledge, although quite low, is likely higher than would be seen in a broader patient 
population. The study also indicated high levels of medication adherence for both 
questionnaire responders and non-responders relative to other recent studies.32,56,78-81 
The PDC values in this study are higher than other studies likely due to the high 
proportion of prevalent users in the cohort and the use of mailed prescriptions in the VA 
system. The mailing service likely reduces barriers to having medication on hand relative 
to other systems. While an important consideration, the mailing system does not negate 
the relationship of PDC to actual adherence because VA patients are still required to 
request a refill each time one is needed. In other words, there is no automatic, time-
based refilling system. The primary analysis used a short 6-month allopurinol-free period 
of observation before first allopurinol prescription, which may have led to 
misclassification due to allopurinol nonadherence. However, a sensitivity analysis using 
a 1-year period did not substantially change point estimates. 
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In summary, I found that a very low proportion of gout patients receiving ULT know 
their treatment goal. This information provides insight into one broadly untapped 
pathway to improve the widely reported suboptimal outcomes in gout. More research on 
prospective strategies to incorporate SU goal information into efforts in shared-decision 
making, quality improvement projects, self-management programs, or educational 
materials in gout is needed. 
Chapter 3: Medication Adherence as a Mediator of 
Optimal Outcomes in Gout  
3.1 Background 
Gout has a well-understood etiology for which efficacious, low-cost, and well-
tolerated treatments are available. Additionally, there is broad international consensus 
on best practices among gout management guidelines,38,49,50,62 including achievement of 
optimal outcomes through maintenance of serum urate (SU) below a 6.0 mg/dl target. 
Recent studies implicate urate lowering therapy (ULT) nonadherence and suboptimal 
dosing strategies as major barriers to achieving the SU target.32,47 However, little 
progress has been made toward improving gout patients’ outcomes,32,82 and it remains 
largely unknown how patient and provider behaviors interact to facilitate achievement of 
target SU goals. 
Medication adherence to allopurinol among gout patients is widely reported to be low 
with only 35-45% considered adherent by pharmacy refill measures.32,56 In a study of 
more than 13,000 gout patients initiating allopurinol, representing over 90% of 
prescribed ULTs,32 adherence was the single strongest predictor of SU goal 
achievement. Among the first studies to report this finding, adherent patients were more 
than 2.5-times as likely to achieve SU levels below 6.0 mg/dl compared to nonadherent 
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patients. However, associations between adherence and treatment outcomes are 
confounded by the “healthy adherer” effect where adherent individuals tend to also be 
more actively engaged or “activated” in promoting their health generally.57 Patient 
activation is defined as the knowledge, skills and confidence required for patients to be 
actively involved in their own care and has been associated with many healthful 
behaviors.67,68,83 Importantly, there have been no studies accounting for patient 
activation when examining the association of medication adherence with gout outcomes. 
In addition to patient factor effects, current prescribing practices likely contribute to 
suboptimal outcomes. One of these practices, ULT dose escalation, directly affects SU 
goal achievement.32 Importantly, if ULT is initiated, current understanding requires dose 
escalation to SU goal for its full therapeutic benefits to be realized.38,49 To maintain a 
patient on ULT without appropriately escalating the dose is a case of clinical inertia, 
defined as a provider not initiating or intensifying a treatment when indicated.84 Other 
provider factors may indirectly affect outcomes by impacting medication adherence. For 
instance, gout flares accompanying ULT initiation have been reported as a potential 
cause of nonadherence.55,79 These so-called “initiation flares”, however, can be limited 
by using low ULT starting doses and appropriate anti-inflammatory prophylaxis.85-87 This 
potential causal pathway connecting low ULT starting dose to SU goal attainment 
through medication adherence has never, to my knowledge, been studied.  
For this study, I adopted the Chronic Care Model (CCM) and chose to focus on 
patient and provider factors given the strong evidence of their impact. Specifically, I 
examined the association of patient and provider factors with SU goal achievement 
among gout patients taking allopurinol. I hypothesized that two patient (medication 
adherence and patient activation) and three provider factors (allopurinol dose escalation, 
low starting dose and anti-inflammatory prophylaxis) would be associated with SU goal 
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attainment. Further, I hypothesized that medication adherence would mediate, at least in 
part, associations of other patient and provider factors with SU goal achievement.  
3.2 Methods 
The design, setting, sample and procedures for this study are described in the 
Section 2.2 Methods. Briefly, this cross-sectional study linked patient questionnaire 
responses with historical medical and pharmacy dispensing records data from all gout 
patients receiving care at a single Midwestern VA medical center to determine patient 
and provider factors associated with optimal gout management. The study used the 
same inclusion and exclusion criteria for a final cohort of 612 patients (Figure 2) 
Primary Outcomes 
Laboratory records were used to determine the primary outcome of whether patients 
ever achieved SU goal (< 6.0 mg/dl) after allopurinol initiation. Two alternative measures 
of goal attainment were used for sensitivity analyses. Recognizing that some patients 
may not have a follow-up SU on record, I constructed an alternative measure of SU goal 
attainment using the same SU goal (< 6.0 mg/dl), but also classifying patients without a 
SU on record as not achieving goal. This reflects expert consensus that follow-up SU 
assessments are required for optimal care.38,49 The second alternative used the final SU 
value on record to determine goal attainment.  
Allopurinol medication adherence was considered as both an outcome and a 
predictor variable due to its hypothesized role as a mediator. I was interested in the 
implementation component of adherence.88 Specifically, I sought to determine the extent 
that a patients’ actual medication taking behavior corresponded to prescribed regimens 
once both the provider and patient indicated an intent to establish long-term treatment as 
represented by the first allopurinol fill. Allopurinol adherence was determined by 
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calculating the proportion of days covered (PDC) during a fixed, 360-day period 
beginning on the day of the patient’s first prescription fill. This provided a sufficiently 
long, fixed observation period to determine adherence nearest therapy initiation (“early” 
adherence). A secondary measure of adherence used in sensitivity analysis was the 
PDC calculated during a 360-day period beginning the day of the patient’s first 
allopurinol prescription fill after August 1, 2011 (“recent” adherence). Together, the two 
measures provided a method for understanding the potential effect of temporal distance 
between measures. A PDC ≥ 0.8 was considered adherent and can be intuitively defined 
as any patient who was likely to have allopurinol available to use on at least 8 out of 
every 10 days observed.32,56,79  
Predictor Variables 
As noted in Chapter 2, the Patient Activation Measure (PAMTM) was used to quantify 
self-perceived knowledge, skills, and confidence needed to manage health.67,68 
Importantly, if a patients’ PAM increases over time, their health behaviors improve also 
suggesting that activation could be a target for future interventions.89,90 The PAM score 
distribution for this study was similar to the mean ± standard deviation (SD) of 56.8 ± 
10.0 observed in a large sample of chronic disease patients.91 Importantly, PAM was 
correlated with gout-specific knowledge (r = 0.24, p < 0.001) and confidence in gout 
treatment plan (r = 0.38, p < 0.001) which were collected in this study to assess PAM’s 
convergent validity in gout. Gout-specific knowledge was assessed using the six multiple 
choice questions from Chapter 2 (Table 1). Patients’ confidence in their treatment plan 
was assessed using the mean score from four 11-cm visual analog scales (VAS) with 
anchors from “not at all confident” to “completely confident” that covered the following 
topics: 1) discussed medication options to control gout, 2) discussed lifestyle and diet 
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options, 3) able to summarize treatment plan and 4) able to do all tasks in treatment 
plan.  
VA medical and pharmacy refill records were used to determine provider factors in 
gout care including allopurinol starting dose, dose escalation and anti-inflammatory 
prophylaxis. A low starting dose was defined as ≤ 100 mg/day, consistent with ACR gout 
management guidelines.38 Dose escalation was defined as any increase in allopurinol 
from the first dose to the final dose.32 Anti-inflammatory prophylaxis was assessed by 
determining whether a prescription was filled for non-steroidal anti-inflammatory drugs 
(NSAIDs), corticosteroids or colchicine during a window 30 days prior to or within seven 
days after the patients’ first ever allopurinol fill on record or if the patients’ days of supply 
for anti-inflammatory lasted until after the date of their first ever allopurinol fill. 
Other Measures 
A number of covariates were collected from the questionnaire including marital status 
(married versus not), age at first gout attack, and education level (high school graduate if 
patient completed ≥ 12 years of school). To further describe the gout burden in the 
cohort and potential need for improvements in health outcomes, I report patients’ self-
reported number of gout flares in the past six months. 
VA medical and pharmacy dispensing records were used to determine patients’ 
gender, comorbidity burden, estimated glomerular filtration rate most proximate to 
questionnaire completion (GFR, ml/min), body mass index most proximate to 
questionnaire completion (BMI, kg/m2), and concomitant medication use. Comorbidity 
burden was assessed using ICD-9 codes to determine the patient’s Rheumatic Disease 
Comorbidity Index (RDCI) over a 2-year period bracketing the enrollment allopurinol fill 
date.71 Concomitant medication use was determined by counting the number of unique 
medications filled during a 1-year period beginning August 1, 2011.  I used the 25th 
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percentile (seven unique medications) as a cut-off for defining high versus low 
concomitant medication use. I also identified providers’ primary medical specialty to 
account for important practice and patient population differences among specialties.32 To 
determine the providers’ primary medical specialty, I used a combination of unique 
National Provider Identifier and Drug Enforcement Administration codes. I then assigned 
providers’ primary medical specialty according to which clinic code was most often 
associated with their prescriptions. For descriptive purposes, medical specialty was 
reported in 3 categories (rheumatology, primary care, and other). For analysis, two 
categories were used (rheumatology versus other) because the primary care and other 
categories performed similarly. 
Statistical Analysis 
Chi-squared, Fisher’s exact, Wilcoxon rank sum and t tests were used for 
comparisons of group characteristics as appropriate. As preliminary analysis for 
mediation testing, the association of patient activation and three provider factors 
(allopurinol dose escalation, low-dose initiation, and anti-inflammatory prophylaxis) with 
medication adherence was examined using multivariable logistic regression. All four pre-
specified factors were entered into the model and maintained regardless of statistical 
significance. Covariates from Table 5 were entered into the model if the univariate p-
value was < 0.20 to ensure important independent variables were not overlooked. 
Covariates maintained in the model were identified through a manual backwards 
stepwise selection using a p > 0.05 criterion. Interaction terms were considered for the 
four patient and provider factors and also removed at p>0.05. A similar process was 
used to determine associations with SU goal attainment while including medication 
adherence as a patient factor. To determine the optimal combination of five patient and 
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provider factors, I used the Akaike Information Criteria (AIC) where the lowest AIC 
indicated the best fitting model.  
Mediation by medication adherence was tested using a counter-factual approach 
with delta-method 95% confidence intervals.92 Specifically, I examined whether 
medication adherence mediated the association of the other four pre-specified factors 
with achievement of SU goal. Mediation analysis is useful for understanding many types 
of potential causal pathways, but it can be especially helpful when a predictor variable X 
has a direct association with an outcome Y, but may be inversely associated with the 
same outcome through a mediator M.93 A hypothetical example of this “inconsistent 
model” would be workers’ ability to make error-free widgets where a worker’s intelligence 
(X) is directly associated with fewer errors (Y), but where intelligence also promotes 
boredom (M) in turn increasing errors.94 To further illustrate mediation and inconsistent 
models, I provide a directed acyclic graph depicting a hypothesized inconsistent model 
of mediation proposed in this study (Figure 3). 
In sensitivity analyses, I determined whether results substantially changed when 
considering whether patients used non-VA pharmacies for any medications, if they 
received help taking medications, or had non-VA providers help manage their gout, 
obtained through self-report. I considered alternative measures of SU goal attainment 
and medication adherence as described above. Given the low frequency of missing 
data, complete case analysis was used with the exception of sensitivity analyses where 
missing SU goal attainment values were imputed as described under primary outcomes. 




Figure 3  Conceptual Diagram of an Inconsistent Mediation Model in Gout 
Mediation analysis is useful for understanding potential causal pathways. It can be especially helpful for 
understanding “inconsistent models” where a predictor variable X has a direct association with an outcome 
Y, but may be inversely associated with the same outcome through a mediator M (25). Here I depict an 
inconsistent model proposed in this study. A low starting dose (X) is directly associated with a lower odds of 
reach serum urate (SU) goal attainment (Y), but a low starting dose also promotes medication adherence 




As previously reported in Chapter 2, the questionnaire response rate was 62% (n = 
886). The cohort size for the primary analysis, after applying final exclusion criteria, was 
612 individuals (Figure 2). Questionnaire responders were similar to non-responders, 
except that responders were more likely to receive their first prescription from a 
rheumatology office than a primary care or other office, were more adherent to 
allopurinol, and were more likely to have their SU checked within the first 2 years after 
allopurinol initiation.  
The median duration from first allopurinol prescription to questionnaire mailing was 
6.0 years (interquartile range 3.2 to 10.3). The prevalence of ever reaching SU goal was 
71% (379/531) in patients whose SU was measured following allopurinol initiation and 
62% (379/612) when absence of SU measurement during follow-up was considered as a 
failure to achieve goal. Forty-nine percent (49%) of patients had their SU checked within 
1 year of allopurinol initiation while 66% had SU checked by the end of 2 years. Overall, 
43% of gout patients experienced at least one attack in the previous 6 months with a 
substantial number (28%) reporting more than one attack during that period. Table 5 
displays other patient characteristics.   
Associations with Medication Adherence 
Considering unadjusted bivariate associations for early adherence (Table 5), 
adherent patients (63% of cohort) were slightly older than nonadherent patients (72.8 vs. 
70.9 years, p = 0.036), had their first gout attack at an older age (52.7 vs. 49.7 years, p = 
0.028), higher BMI (32.8 vs. 31.7 kg/m2, p = 0.033), greater comorbidity (RDCI 2.9 vs. 
2.7, p = 0.030), lower activation scores (PAM 58.3 vs. 60.3, p = 0.0497) and were more 
likely to receive a low starting dose of allopurinol (36% vs. 27%, p = 0.014). Neither dose 
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escalation nor anti-inflammatory prophylaxis were associated with medication 
adherence. In sensitivity analysis assessing recent adherence rather than early 
adherence, activation and low starting dose were no longer associated with adherence 
(data not shown). Early and recent adherence were moderately correlated (r = 0.49, p < 
0.001). Other factors reaching the threshold for initial inclusion in the adjusted model 
were gender, marital status, loop diuretic use, concomitant medication use, and RDCI. 
Of the five patient and provider factors examined in adjusted models, only low starting 
dose was associated with higher treatment adherence (OR 1.82, 95% CI 1.20 to 2.76) 
(Table 6). 
Associations with SU Goal Attainment 
Considering unadjusted associations with SU goal attainment, patients at SU goal 
had higher activation scores (59.8 vs. 56.2, p = 0.01) and were more likely to be 
adherent (76% vs. 66%, p = 0.014) than those not at SU goal. Patients at SU goal were 
less likely to receive a low starting dose (27% vs. 48%, p < 0.001). Only 7.5% of all 
patients received a final dose over 300 mg/day including only 12 (6%) of the 200 
patients who began at a low starting dose. Though not statistically significant, patients 
achieving SU goal were more likely to receive allopurinol dose escalation (36% vs. 28%, 
p=0.08). Patients achieving SU goal had a higher GFR (68.6 vs. 58.2 ml/min, p < 0.001) 
and were more likely to be seen by a rheumatologist (7% vs. 1%, p = 0.036) compared 
to patients not achieving SU goal. Loop diuretic use and male gender also reached the 
threshold (p < 0.20) for consideration in the adjusted model.  
In multivariable analysis, three of the five patient and provider factors were 
associated with SU goal attainment while a fourth, patient activation, did not reach 
statistical significance, but did improve model performance (AIC 514 with activation vs. 
516 without). While both medication adherence (OR 2.35; 95% CI 1.50 to 3.68) and 
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dose escalation (OR 2.48; 95% CI 1.45 to 4.25) were strongly associated with SU goal 
attainment, low starting dose demonstrated an inverse association (OR 0.21; 95% CI 
0.12 to 0.35). 
Medication Adherence as a Mediating Factor 
In the mediation model, I isolated a positive effect of low starting dose on SU goal 
attainment indirectly through early adherence (OR 1.11; 95% CI 1.02 to 1.20) (Table 6). 
Isolating this effect maintained the direct, inverse relationship of low starting dose with 
SU goal attainment (OR 0.21; 95% CI 0.12 to 0.37). Small effect size increases were 
noted for the direct effect of medication adherence and dose escalation in the mediation 
model relative to the multivariable logistic regression model. 
Sensitivity Analyses 
In sensitivity analysis considering recent adherence (Table 7), the association 
between low starting dose and adherence was, as expected, attenuated and no longer 
significant. The change did not substantially increase the association of adherence with 
patient activation, as might have been expected given the shorter temporal distance 
between the two after the change. Associations between adherence and provider factors 
were also unaffected by the change to recent adherence. Other listed sensitivity 
analyses for achieving SU goal are available in Table 8. In general, effect size changes 
were modest while the direction and relative effects of the five patient and provider 
factors remained largely consistent. 
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Table 5  Bivariate Associations with Adherence and Serum Urate Goal Attainment 
 
Overall  
n = 612 
Adherent  
(PDC ≥ 0.8) 
n = 363 
Nonadherent  
(PDC < 0.8) 
n = 229 
Serum Urate  
< 6.0 mg/dL 
n = 379 
Serum Urate  
≥ 6.0 mg/dL 
n = 152 
Age, yrs. 72.1 (10.7) 72.8 (10.0) 70.9 (11.6) 71.8 (10.4) 72.4 (10.4) 
Male, % 98 98 99 99 † 97 † 
Married, % 54 57 50 54 54 
Age at first Attack, yrs. 51.6 (16.2) 52.7 (16.5) 49.7 (15.6) 51.0 (15.8) 51.7 (17.0) 
BMI, kg/m2 32.5 (6.3) 32.8 (6.5) 31.7 (5.8) 32.5 (6.3) 33.1 (6.9) 
GFR, ml/min 65.5 (22.3) 65.0 (21.7) 66.3 (23.2) 68.6 (21.8) 58.2 (21.5) 
RDCI 2.8 (1.5) 2.9  (1.5) 2.7 (1.5) 2.8 (1.4) 2.8 (1.5) 
High School Graduate, % 89 89 88 89 89 
Diuretic Use, %      
Loop 27 30 22 26 33 
Thiazide 22 22 21 21 22 
Concomitant Med Use, % 74 77 66 75 72 
Duration of Allopurinol Use, yrs 6.0 [3.2–10.3]  6.2 [3.2–10.4] 5.9 [3.2–10.0] 6.8 [3.5–10.9] 5.1 [2.8–9.8] 
      
Activation Score 59.1 (11.4) 58.3 (11.0)  60.3 (12.0) 59.8 (11.2) 56.9 (12.1) 
PDC 0.79 (0.25) - - 0.95 [0.81 – 1.00]* 0.92 [0.65 – 0.99]* 
Adherent, % 63 - - 76 66 
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Low Starting Dose, % 33 36 27 27 48 
Anti-Inflammatory Proph, % 54 54 55 56 55 
Dose Escalation, % 31 30 31 36 28 
Prescriber Specialty, %      
Rheumatology 5 5 4 7 1 
Primary Care 87 88 87 84 92 
Other 8 8 8 10 7 
All values are %, mean (standard deviation) or median [interquartile range]. Bold values represent statistically significant differences at p < 0.05. † Fischer’s 
Exact Test. * Wilcoxon rank sum test. Analysis represents non-missing data. No variable had >3% missing data except age at first attack (6.5%), activation 
score (7.5%) and serum urate (13%).  
 
 PDC, proportion of days covered; BMI, body mass index; GFR, estimated glomerular filtration rate; RDCI, Rheumatic Disease Comorbidity index 
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Table 6  Adjusted Associations of Early Adherence and SU Goal Attainment 
 Adherent 
(PDC ≥ 0.8)† 
Serum Urate 
< 6.0 mg/dL ‡ 
Indirect Effect Via 
Adherence* Direct Effect* 
Patient Factors     
Activation Score 0.99 [0.98 to 1.01] 1.02 [1.00 to 1.03] 1.00 [1.00 to 1.00] 1.02 [1.00 to 1.04] 
Adherent (PDC ≥ 0.8) - 2.35 [1.50 to 3.68] - 2.39 [1.51 to 3.78] 
Provider Factors     
Low Starting Dose 1.82 [1.20 to 2.76] 0.21 [0.12 to 0.35] 1.11 [1.02 to 1.20] 0.21 [0.12 to 0.37] 
Anti-Inflammatory Proph 0.91 [0.63 to 1.30] 1.07 [0.69 to 1.66] 0.98 [0.93 to 1.05] 1.15 [0.74 to 1.82] 
Dose Escalation 0.80 [0.53 to 1.23] 2.48 [1.45 to 4.25] 0.97 [0.89 to 1.04] 2.52 [1.47 to 4.34] 
All values represent odds ratio [95% confidence interval]. The 95% confidence intervals for direct and indirect effects were determined 
using the delta method. † Model adjusts for age and body mass index. ‡ Model adjusts for estimated glomerular filtration rate and provider 
specialty. * Model adjusts for all covariates in early adherence and serum urate goal attainment models listed above. Bold terms represent 




Table 7  Sensitivity Analysis: Adjusted Associations of Recent Adherence and Serum Urate Goal Attainment 
 Adherent 
(PDC ≥ 0.8)† 
Serum Urate 
< 6.0 mg/dL ‡ 
Indirect Effect Via 
Adherence* Direct Effect* 
Patient Factors     
Activation Score 1.01 [1.00 to 1.03] 1.02 [1.00 to 1.04] 1.00 [1.00 to 1.00] 1.02 [1.00 to 1.04] 
Adherent (PDC ≥ 0.8) - 2.25 [1.40 to 3.62] - 2.22 [1.36 to 3.61] 
Provider Factors     
Low Starting Dose 1.38 [0.88 to 2.17] 0.23 [0.14 to 0.38] 1.05 [0.99 to 1.11] 0.22 [0.13 to 0.37] 
Anti-Inflammatory Proph 0.88 [0.59 to 1.31] 1.10 [0.71 to 1.70] 0.99 [0.94 to 1.03] 1.17 [0.74 to 1.83] 
Dose Escalation 0.65 [0.42 to 1.03] 2.50 [1.46 to 4.27] 0.94 [0.88 to 1.01] 2.52 [1.46 to 4.35] 
All values represent odds ratio [95% confidence interval]. The 95% confidence intervals for direct and indirect effects were determined 
using the delta method. † Model adjusts for age, body mass index and concomitant medication use (greater than 7 concomitant 
medications). ‡ Model adjusts for estimated glomerular filtration rate and provider specialty. * Model adjusts for all covariates in adherent 
and serum urate goal attainment models listed above. PDC, Proportion of Days Covered. 
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in Gout Care 
(n=427) 
Excluding Patients with 
any Prescriptions from 
Pharmacy other than VA 
(n=394) 
Patient Factors     
Activation Score 1.02 [1.00 to 1.03] 1.02 [1.00 to 1.05] 1.02 [1.00 to 1.04] 1.02 [1.00 to 1.05] 
Adherent (PDC ≥ 0.8) 2.35 [1.50 to 3.68] 2.23 [1.37 to 3.62] 2.12 [1.32 to 3.41] 2.26 [1.38 to 3.70] 
Provider Factors     
Low Starting Dose 0.21 [0.12 to 0.35] 0.23 [0.13 to 0.41] 0.25 [0.15 to 0.43] 0.22 [0.12 to 0.39] 
Anti-Inflammatory Proph 1.07 [0.69 to 1.66] 1.15 [0.71 to 1.86] 0.98 [0.61 to 1.56] 1.10 [0.67 to 1.79] 
Dose Escalation 2.48 [1.45 to 4.25] 2.54 [1.41 to 4.57] 1.98 [1.13 to 3.45] 2.36 [1.31 to 4.22] 
All values represent odds ratio [95% confidence interval]. All models adjust for estimated glomerular filtration rate and provider specialty. PDC, 














with no SU 
measurements as not 
achieving SU goal 
(n=562) 
Using last SU on 
record 
(n=490) 
Using last SU on 
record & classifying 
no SU 
measurements as 
not achieving SU 
goal (n=562) 
Patient Factors     
Activation Score 1.02 [1.00 to 1.03] 1.01 [1.00 to 1.03] 1.00 [0.99 to 1.02] 1.00 [0.99 to 1.02] 
Adherent (PDC ≥ 0.8) 2.35 [1.50 to 3.68] 1.88 [1.28 to 2.77] 2.09 [1.40 to 3.10] 1.88 [1.30 to 2.72] 
Provider Factors     
Low Starting Dose 0.21 [0.12 to 0.35] 0.25 [0.15 to 0.39] 0.30 [0.19 to 0.48] 0.31 [0.20 to 0.48] 
Anti-Inflammatory Proph 1.07 [0.69 to 1.66] 1.16 [0.80 to 1.70] 1.08 [0.73 to 1.58] 1.13 [0.79 to 1.62] 
Dose Escalation 2.48 [1.45 to 4.25] 3.68 [2.24 to 6.05] 2.12 [1.33 to 3.38] 2.92 [1.86 to 4.58] 
* This column is repeated to facilitate easy comparison. All values represent odds ratio [95% confidence interval]. All models adjust for estimated 




In gout patients treated with allopurinol, medication adherence, dose escalation, and 
low starting dose were all strongly associated with SU goal attainment even after 
adjustment for patient activation and other relevant covariates. Interestingly, in the 
mediation model, low starting dose was indirectly associated with better SU goal 
attainment through its positive effect on early adherence while simultaneously being 
directly associated with worse SU goal attainment. The positive effect of low starting 
dose on medication adherence reflects evidence that smaller decreases in SU level 
during treatment initiation are associated with fewer treatment “initiation flares” and 
better adherence among patients.55,86 I observed that the direct association with SU goal 
attainment was likely driven by the low prevalence of dose escalation observed in this 
study. Only about 1 in 3 patients ever received dose escalation of allopurinol, and only 
about 1 in 17 initiating allopurinol at a low starting dose ever progressed beyond 300 
mg/day, a dose that is insufficient in up to 60% of patients.40 These novel findings 
suggest that a strategy of low allopurinol starting dose followed by appropriate dose 
escalation to SU goal maximizes goal attainment by promoting both early allopurinol 
adherence and long-term lowering of SU.  
Contrary to my initial hypothesis, an important and novel finding is the relatively weak 
association observed between patient activation and SU goal attainment. Patient 
activation is one of the most promising measures currently available for ascertainment of 
a patient’s engagement in promoting their health. It is associated with health 
maintenance behaviors, such as proper diet, exercise and self-reported medication 
adherence,83,89-91 all of which are promoted in gout management guidelines.38,49 In this 
study, higher activation scores were associated with higher levels of both gout-specific 
knowledge and confidence in treatment plans indicating the PAM measures some level 
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of gout-specific engagement. However, this study’s findings suggest that patient 
activation may have limited impact on whether or not a gout patient reaches SU goal. 
This is consistent with literature showing that health behaviors such as targeted dietary 
modifications do not typically bring SU levels below target concentrations.95 Future 
studies will be needed to confirm whether or not patient activation is associated 
medication adherence as this study appears to be the first to investigate the association 
using an objective measure of adherence. 
Beyond the novel findings regarding patient activation and mediation by adherence, 
results of this study are consistent with other studies of SU goal attainment in 
observational settings. The finding of an association between medication adherence and 
SU goal attainment (OR 2.35; 95% CI 1.50 to 3.68) is consistent with the OR of 2.52 
(95% CI 2.41 to 3.01) observed in the only other study to assess this association.32 My 
finding that dose escalation is strongly associated with SU goal attainment is novel, but 
consistent with other studies showing increasing odds based on final allopurinol 
dose.32,96 I also verified that, in the context of inadequate dose escalation, a low starting 
dose of allopurinol is directly associated with failure to reach SU goal.32 Given the 
importance of low starting dose in both promoting early adherence and minimizing risk of 
allopurinol hypersensitivity reactions,97 overcoming clinical inertia related to dose titration 
represents a key target for future interventions.  
Anti-inflammatory prophylaxis was not associated with adherence or SU goal 
attainment. However, the findings should be considered in the larger context of the 
literature. Clinical trial data indicates that anti-inflammatory prophylaxis is effective at 
reducing attacks during therapy initiation.85-87 Thus, anti-inflammatory prophylaxis 
remains an important best practice in optimal gout management.37 
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While care was taken to ensure appropriate relative timing of measures from 
electronic records, linkage with questionnaire data makes the study inherently cross-
sectional precluding causal interpretations. Additionally, the study design promoted a 
predominantly prevalent user cohort which in turn likely led to more individuals being 
adherent (63%) and achieving SU goal (62-71%) in this study relative to other studies 
using electronic health records.32 As I showed, it is important to recognize the ways in 
which questionnaire responders differ from non-responders. Notwithstanding this caveat, 
the high response rate (62%) and representative distribution of PAM scores gives us 
confidence that the estimates of associations are robust within the inherent limitations of 
mailed questionnaires.91 Finally, the measure of adherence was based on prescription 
refill data, which likely overestimates the number of days medication was taken correctly.  
The World Health Organization and others have identified patients and health care 
system design as important dimensions for improving medication adherence and patient 
outcomes.98,99 Approaches targeting these dimensions would be appropriate for 
improving important modifiable factors in this study. Specifically, improved adherence, a 
strong predictor of SU goal attainment in this study, among patients with similar diseases 
has been achieved by direct-to-patient communication and modifying patient routines.100-
102 Furthermore, health care system factors, such as clinical decision support or system 
redesign efforts, have shown promise in improving prescribing behaviors.103,104 By 
implementing these approaches in gout care, we may begin to address the important 
barriers to optimal outcomes reported here. 
In conclusion, medication adherence and low allopurinol starting dose combined with 
appropriate ULT dose escalation represent promising targets for future gout quality 
improvement efforts. While targeting patient activation or engagement in personal health 
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maintenance may have other important health benefits, this study indicates that such 
efforts may have a limited impact on SU goal attainment. 
Chapter 4: Allopurinol Dose Escalation and Mortality 
Among Gout Patients 
4.1 Background 
Hyperuricemia and gout are independently associated with increased 
mortality.28,30,31,105 A majority of this increase in mortality risk is thought to be attributable 
to excess cardiovascular disease,106 but may also be associated with increased cancer 
mortality.107 Multiple studies have shown that hyperuricemia increases interstitial 
inflammation and decreases endothelial function, a well-characterized surrogate for 
cardiovascular risk.106,108 By contrast, urate lowering therapies (ULTs) such as allopurinol 
have been associated with improved endothelial function, reduced blood pressure, and 
improved glomerular filtration rate (GFR).109-111 Dubreuil et al. and others have gone 
further to show that allopurinol may even lower mortality risk among gout patients.112,113 
However, it remains unknown whether a dose relationship exists between ULT and 
reductions in mortality. 
Allopurinol dosing strategies are a critical point of interest in gout care. Current 
guidelines recommend that patients be started on a low dose, ≤ 100 mg daily, and then 
titrated up slowly.38 While past randomized clinical trials (RCTs) of ULTs have used 
static dosing strategies,40-42 such strategies are suboptimal and should now be 
considered unethical. Future studies will likely be required to dose escalate therapy until 
patients meet serum urate (SU) goal. This ethical requirement, however, impedes our 
ability to understand if ULT dose escalation strategies reduce mortality in gout. Further 
limiting are the large sample sizes and lengthy follow-up duration required to determine 
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whether appropriate ULT dose escalation favorably impacts mortality and other long-
term outcomes. Evidence that these requirements are substantial challenges for study 
design and cost can be observed in recent diabetes efforts.114,115 
Observational studies of comparative effectiveness can be an important complement 
to RCTs especially for definitive long-term outcomes such as mortality.116 It has been 
shown that a substantial portion of primary care providers, responsible for approximately 
95% of gout management, use a static ULT dosing strategy for gout patients.32 However, 
a small but meaningful number of providers use a dose escalation strategy providing a 
potential opportunity for comparison. Using a national population of gout patients, I 
investigated the effect of ULT dose escalation on mortality. Specifically, I hypothesized 
that patients receiving dose escalation would have a lower all-cause and cause-specific 




I identified a population of gout patients using Veterans Health Administration (VHA) 
data from 1999 to 2010. The VHA has provided care for between 5 and 10 million retired 
US military enrollees each year since 2001. Data from the VHA’s electronic medical 
records and pharmacy prescribing represent longitudinal care provided at 152 medical 
centers and 1,400 additional community-based outpatient clinics nationwide. This data, 
including demographics, outpatient and inpatient visits, laboratory results, and pharmacy 
dispensing, was accessed in the VHA’s Corporate Data Warehouse through the VA 
Informatics and Computing Infrastructure (VINCI).117 Many studies indicate the 




The target cohort for this study was defined as any gout patient ≥ 40 years old 
prescribed incident allopurinol between October 2001 and December 2008. Gout for this 
study was defined as having at least 1 International Classification of Disease (ICD-9) 
code for gout prior to the incident allopurinol fill with a second ICD-9 code for gout 
separated by at least 30 days and occurring prior to the beginning of time at risk 
(described below). Also considered to be a first-line ULT,38 febuxostat was approved on 
February 2009 and only available to clinical trial participants prior to that date. Patients 
were required to have a record of hyperuricemia, defined for this study as SU ≥ 8.0 
mg/dl to reflect a gout population most likely to need dose escalation, and at least 1 year 
of observability without allopurinol prior to the incident allopurinol date. Observability was 
defined as having at least 1 annual VHA primary care or rheumatology visit and filling at 
least one prescription every 6 months.120 Patients were excluded if they had an 
estimated glomerular filtration rate < 30 ml/min, were involved in a clinical trial for ULT 
during observation, or had history of dialysis, organ transplantation, malignancy, or 
tumor lysis syndrome.112,113 These exclusions were intended to limit the population of 
interest to patients for whom gout was the primary indication for allopurinol receipt.  A 
total of 31,336 patients met the eligibility criteria for the study and 25,379 of those had 
complete data required for propensity score matching as described below (Figure 4). 
Mortality Outcomes 
The primary outcomes for this study were all-cause and cause-specific 
cardiovascular and cancer mortality as defined using the National Death Index (NDI). 
The NDI is a centralized database of death record information reflecting state vital 
statistic office records and maintained by the Centers for Disease Control and 
Prevention. Death records were requested from and matched by VHA staff at the 
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Suicide Data Repository which maintains NDI records for VHA. The records include date 
of death and cause of death as recorded by ICD-10 codes. Cardiovascular mortality was 
defined as any mortality attributed to an ICD-10 code within Chapter IX (I00-I99) and 
cancer mortality was defined as an ICD-10 within Chapter II (C00-D48). Competing risks 
for cardiovascular and cancer mortality were other causes of mortality and cancer or 
cardiovascular mortality, respectively. All-cause mortality was also assessed. 
Primary Predictor Variable 
Allopurinol dose escalation was the primary predictor variable. Dose escalation was 
defined over a 2-year ‘dose escalation’ period which I estimated would encompass 
planned dose escalation strategies in practice. Using the dataset in Chapters 2 and 3, I 
found that approximately 70% of all allopurinol dose escalation events occurred within 2 
years of a new allopurinol prescription. Patients were identified as “dose escalators” if 
their final average daily dose within the 2-year period was greater than their initial 
average daily dose. Patients were allowed to switch to febuxostat and dose 
equivalencies to allopurinol were estimated based on clinic trial data demonstrating that 
similar proportions of patients on 300 mg/day of allopurinol and 40 mg/day of febuxostat 
reach SU goal (42% vs. 45%, respectively).42 Thus, a patient switching from allopurinol 
100 mg daily to febuxostat 40 mg daily was considered to be a dose escalator. For this 
analysis, I estimated that the three febuxostat doses observed during follow-up (40, 80 
and 120 mg/day) were approximately equivalent to 300, 600 and 900 mg/day of 
allopurinol, respectively. Within-prescription dose escalations were accounted for by 
review of the medical label instructions (commonly referred to as the medication sig). 
Patients having within-prescription dose escalations were categorized as dose 
escalators if the final average daily dose of the sig for their last prescription fill during the 
dose escalation period was greater than the initial dose from the sig of the incident 
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allopurinol fill. To identify dose escalation sigs, unique sigs were reviewed randomly and 
iteratively in samples of 200 to detect common characteristics of dose escalation sigs. 
Any sigs matching those characteristics were removed for full analysis where each 
unique sig was reviewed individually and labeled with the starting average daily dose 
and final average daily dose by two reviewers. Any discrepancies were reviewed 
together to establish consensus or decided by a third reviewer if no consensus could be 
reached. After 2 consecutive random draws found no new common identifiers, 1,000 of 
the remaining unreviewed sigs were randomly drawn to estimate the sensitivity of this 
identification method. Only 0.5% of the 1,000-sig random sample were identified as dose 
escalation sigs translating into an estimated 98% sensitivity for using this method on all 
sigs. Because each sig identified for full analysis was individually assessed and verified 
by a second reviewer, the specificity is expected to approach 100%. 
Propensity Matching 
While some differences in whether an individual patient is appropriately dose 
escalated may be due to random chance, patients receiving dose escalation may also 
systematically differ from those not receiving dose escalation. In order to mitigate 
confounding by indication, I used propensity score matching to balance baseline 
confounders and prognostic variables between two groups: dose escalators and non-
escalators. My methods build on prior work by Dubreuil et al. who designed a propensity 
matching approach for allopurinol use among hyperuricemic patients with and without 
gout.112 For each patient, I calculated the predicted probability (propensity score) of 
receiving dose escalation over the 2-year dose escalation period using a logistic 
regression equation. To address time trends in allopurinol use and confounders prior to 
matching, patients were sorted into accrual blocks of approximately 6-months in length 
from October 2001 to December 2008 (14 blocks) based on the date of the incident 
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allopurinol fill. Within each accrual block, I created a matched sample by matching dose 
escalators and non-escalators 1:1 based on the logit of the propensity score using 
calipers to limit the allowable difference in scores between matches. I used a caliper of 
0.2 times the standard deviation of the logit.121  I used a greedy match algorithm such 
that, after matching to a dose escalator, non-escalators were removed from the pool of 
potential matches.121 
The variables used to develop the propensity score estimation were assessed over a 
baseline period of up to 2-years prior to the incident allopurinol date. Baseline 
characteristics included demographics, body mass index (BMI, kg/m2), comorbidities, 
medication use, laboratory values indicating cardiovascular risk, health care utilization 
and gout-specific factors. Demographic variables were defined for age at incident 
allopurinol date and sex. Comorbidities included hypertension, cardiovascular disease 
and diabetes identified by ICD-9 codes. Patients’ comorbidity burden was further 
described using the validated Rheumatic Disease Comorbidity Index (RDCI).71 
Medication use related to cardiovascular risk was recorded for each of the following 
categories: β blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin II 
receptor blockers (ARBs), calcium channel blockers (CCBs), loop diuretics, thiazides, 
statins, fibrates, aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), metformin, 
other oral hypoglycemic agents, and insulin. Laboratory values for total cholesterol 
(g/dL), albumin (g/dL) and estimated glomerular filtration rate (eGFR, mL/min/1.73 m3 
based on serum creatinine using the Modification of Diet in Renal Disease equation)122 
were identified using available laboratory data from the date nearest incident allopurinol 
during the 2-year baseline period. The total number of primary care visits during this 
baseline period was used as a proxy for health care utilization. The number of outpatient 
gout diagnoses on record and the presence of an inpatient gout diagnosis as the primary 
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discharge diagnosis during the baseline period were used as proxies for gout burden. 
Patients were also classified based on presence of a rheumatology visit or consult 
during the baseline 2-year period. Finally, the patients’ baseline SU concentration 
nearest incident allopurinol date and the index allopurinol dose were included as gout-
specific factors.  
Assessments for Quality of Care as a Residual Confounder 
Propensity matching may not effectively control for confounding if quality of care 
concurrent to ULT dose escalation is markedly different between dose escalators and 
non-escalators for common comorbidities. For instance, if ULT dose escalators treated 
for hypertension tend to have better control of blood pressure than ULT non-escalators, 
we may be concerned that unmeasured confounding is biasing estimates. In other 
words, it may be that concurrently improving care or healthful behaviors explain some or 
all of the association estimated. To assess for this possibility, I report baseline and 2-
year follow-up values for two process quality variables: percentage of patients with blood 
pressure readings ≥ 140 systolic or 90 diastolic mm/Hg among those treated for 
hypertension (beta-blockers, calcium channel blockers, thiazides, loop diuretics, ACE 
inhibitors or ARBs) and the percentage of patients with a cholesterol > 200 mg/dl among 
those treated for hyperlipidemia (statins or fibrates). I also report the percent of patients 
with complete observability during the 2-year dose escalation period using the same 
aforementioned definition applied to the pre-index period. Patients had to be considered 
‘observable’ during both year periods to be considered observable for the 2-year dose 
escalation period. 
Statistical Analysis 
Baseline characteristics of eligible dose escalators and non-escalators were 
assessed using standardized differences.123 All listed baseline characteristics (Table 10) 
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were used for matching. Balance diagnostics were used to assess the means and 
distributions of baseline characteristics of the matched groups. Means of the matched 
groups were compared using standardized differences.121 Standardized differences of < 
0.1 were considered negligible.121 Continuous variable distributions were compared 
using variance ratios, quantile-quantile plots, and non-parametric density plots.124 I 
confirmed that all variance ratios fell within F-distribution 95% confidence intervals.124 
The plots were visually assessed for deviations in distributions between groups. Non-
linear and interaction terms were subsequently considered if balance diagnostics 
indicated that matching did not adequately balance the means or distributions of 
baseline characteristics.124,125  
Time at risk for both groups began 2 years after the date of incident allopurinol. This 
consistent time period between groups eliminates the potential for immortal time to bias 
risk estimates.126 For instance, an alternative, but naïve approach may have been to 
start time at risk for non-escalators at the time of first allopurinol while waiting for time at 
risk to begin for dose escalators until escalation had occurred. Because only living dose 
escalators would be included in the study using this method, an ‘immortal’ period before 
the escalation event would exist for dose escalators, but not non-escalators. My method 
of determining time at risk eliminates the potential that immortal time could bias risk 
estimates in favor of the dose escalation group. Competing risks regression and 
cumulative incidence plots were used to assess the effect of dose escalation on 
cardiovascular and cancer mortality in the presence of other causes of mortality. A Cox 
proportional hazards model was used to estimate the effect of dose escalation on all-
cause mortality with 95% confidence intervals (CI) based on robust variance estimates 





Figure 4  National Mortality Study Flow Diagram 
Any gout patient ≥ 40 years old prescribed incident allopurinol between October 2001 and December 2008 
was considered for this study. Gout for this study was defined as having at least 1 International 
Classification of Disease (ICD-9) code for gout prior to the incident allopurinol fill with a second gout ICD-9 
code separated by at least 30 days and occurring prior to the beginning of time at risk. At total of 111,694 
met this inclusion criteria. A total of 78,589 patients were excluded based on one or more exclusion criteria. 
Baseline variables were defined for 31,336 eligible patients. Complete data and survival through the dose 
escalation were required for matching leading to the final cohort of 23,746 patients for propensity matching. 
Out of these, 12,130 (51%) were matched using 1:1 propensity score matching. * The SU and eGFR 




Prior to matching, the 6,931 dose escalators were similar to 16,833 non-escalators 
for a majority of the baseline characteristics (Table 9). Only health care utilization 
measures and SU exceeded a standardized difference of 0.1. As expected, those 
receiving dose escalation had a higher average baseline SU (9.6 mg/dL vs. 9.4 mg/dL), 
lower median incident allopurinol dose (100 mg/day vs. 200 mg/day), greater median 
number of baseline primary care visits (9 visits vs. 8 visits over 2 years) and were more 
likely to have a rheumatologist involved in their care (18% vs. 6% with a rheumatologist 
prescribing the baseline allopurinol and 24% vs. 11% with a rheumatology clinic visit 
during baseline).  
Propensity Matching 
Incident allopurinol dates were well distributed over time with the number of eligible 
dose escalators and non-escalators during each accrual block ranging from 345 to 724 
and 896 to 1,474, respectively. After propensity score matching, all baseline 
characteristics were balanced based on standardized differences (all <0.03, Table 9). 
Variance ratios and visual inspection of distributions indicated balanced distributions 
between groups for all continuous baseline variables. Importantly, 99.8% of patients had 
baseline allopurinol doses within 100 mg/d, 76.6% started on the same dose, and those 
with higher doses than their match were evenly distributed between dose escalators and 
non-escalators (11.7% and 11.8%, respectively).  Consistent with a VA gout population, 
the mean age was 64 years and over 99% were male.47 The majority of patients had 
comorbid hypertension, cardiovascular disease or diabetes; use of medications for these 
conditions was common. The propensity matched cohort had similar rheumatology 
contact with 11% having their baseline allopurinol prescribed by a rheumatologist and 
17% having a rheumatology clinic visit. 
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Dose Escalation Practices and Follow-up SU Concentrations 
As noted, 99.8% of patients had baseline doses of allopurinol within 100 mg/day of 
their matched pair. The median dose increase for dose escalators over the 2-year follow-
up was 100 mg/day with 90% of increases ranging from 50 to 300 mg/day. Only 10% of 
patients in the dose escalation group escalated to a final dose greater than 300 mg/day 
(Table 11).  As expected, dose escalators had greater SU goal attainment during follow-
up (31% vs. 12%). However, even among dose escalators, SU goal was achieved by a 
minority of patients.  
All-Cause Mortality 
There were 2,179 deaths occurred during observation with 1,067 occurring in the 
dose escalation group and 1,112 in the non-escalation group. The mortality rates were 
48.4 and 46.3 per 1,000 person-years for dose escalators and non-escalators, 
respectively. This represents a 4% reduction in mortality risk for dose escalators not 
reaching statistical significance (HR 0.96; 95% CI 0.88 to 1.04). Using a cumulative 
incidence plot, there is only a negligible difference in mortality incidence over time 
(Figure 5). 
Cause-Specific Mortality 
There were 479 cardiovascular deaths among dose escalators and 490 
cardiovascular deaths among non-escalators leading to cardiovascular mortality rates of 
20.8 and 21.3 per 1,000 person-years, respectively. For cancer, there were 187 deaths 
among dose escalators and 203 deaths among non-escalators translating to cancer 
mortality rates 8.1 and 8.8 per 1,000 person-years, respectively. Dose escalation was 
not associated with a statistically significant reduction in cardiovascular (HR 0.97; 95% 
CI 0.86 to 1.10) or cancer mortality (HR 0.92; 95% CI 0.75 to 1.12). Referring again to 
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the cumulative incidence plots (Figure 5), there were only small differences in time to 
death between dose escalators and non-escalators after accounting for competing risks. 
Assessment for Quality of Care Residual Confounding 
Assessments for quality of care were done at baseline and follow-up to determine 
whether other factors reflecting quality of care may have changed concurrently with dose 
escalation (Table 12). Observability during follow-up was slightly better for dose 
escalators relative to non-escalators (94% vs. 91%, standardized difference = 0.1), but 
was high overall for both groups. There was no difference in the proportion of patients at 
blood pressure goal at baseline or follow-up among those treated for hypertension. At 
baseline, cholesterol control was similar for dose escalators and non-escalators. By the 
end of follow-up slightly more dose escalators had achieved cholesterol goal than non-
escalators, but the standardized difference remained less than 0.1 (80% vs 78%, 
standardized difference = 0.06). Overall, these findings indicate minimal differences in 




Table 9  Baseline Characteristics of Unmatched and Matched Cohorts 
 




(n = 6,913) 
Non-
Escalators 





(n =  6,065) 
Non-
Escalators 
(n = 6,065) 
Std. 
Diff. 
Demographics       
Age, years 63.8 ± 10.3 64.4 ± 10.6 0.05 64.0 ± 10.4 64.0 ± 10.3 0.01 
Male, % 99.6 99.7 0.02 99.6 99.7 0.01 
BMI, kg/m2 32.6 ± 6.4 32.0 ± 6.2 0.09 32.4 ± 6.3 32.4 ± 6.3 0.01 
Comorbidity       
Hypertension, % 90 89 0.03 90 90 0.02 
Cardiovascular Disease,% 50 47 0.06 49 49 <0.01 
Diabetes, % 38 35 0.06 37 37 0.01 
RDCI, mean 2 [1-3] 2 [1-3] 0.06 2 [1-3] 2 [1-3] <0.01 
Medications       
Β-blockers, % 60 57 0.07 59 59 <0.01 
ACE Inhibitors, % 67 66 0.02 67 67 0.01 
ARBs, % 13 12 0.05 13 13 <0.01 
CCBs, % 43 41 0.03 42 43 <0.01 
Loop Diuretics, % 34 30 0.07 33 33 <0.01 
Thiazides, % 51 50 0.02 51 50 0.01 
Statins, % 63 61 0.03 63 63 0.01 
Fibrates, % 15 13 0.04 14 14 <0.01 
Aspirin, % 33 31 0.03 33 32 <0.01 
NSAIDs, % 71 70 0.02 71 71 <0.01 
Metformin, % 15 15 0.02 15 15 0.01 
Other Hypoglycemics, % 23 21 0.03 22 22 0.01 
Insulin, % 12 10 0.09 11 11 0.01 
Laboratory Measurements       
Serum Urate, mg/dL 9.6 ± 1.6 9.4 ± 1.5 0.18 9.6 ± 1.5 9.6 ± 1.5 0.01 
Cholesterol, mg/dL 180 ± 44 181 ± 43 0.02 181 ± 44 181 ± 43 <0.01 
eGFR, mL/min/1.73 m2 65 ± 21 66 ± 20 0.06 65 ± 21 65 ± 21 <0.01 
Albumin, g/dL 4.0 ± 0.5 4.0 ± 0.5 0.01 4.0 ± 0.5 4.0 ± 0.5 0.01 
Health Utilization Measures       
Incident Allo Dose, mg/d 100 [100-100] 200 [100-300] 1.09 100 [100-100] 100 [100-100] <0.01 
Primary Care Visits,  n 9 [6-14] 8 [6-13] 0.10 6 [9-14] 6 [9-14] <0.01 
Gout Diagnoses,  n 3 [1-5] 3 [1-5] 0.09 3 [1-5] 3 [2-5] 0.02 
Inpatient Gout Diagnosis, % 3 2 0.06 2 2 0.01 
Rheumatology Prescriber,% 18 6 0.35 11 11 0.01 




Baseline characteristics for each group are mean ± SD, percent, or median [interquartile range]. 
Standardized differences (Std. Diff.) are reported for each baseline variable and values less than 0.1 are 
considered negligible. Values are bolded if they are above the 0.1 threshold. Standardized differences are 
the preferred statistic for between group comparisons in propensity studies because the statistic is 
independent of sample size providing a consistent measure before and after matching.124 Review of 
standardized differences in the far right column for the matched cohort indicate successful matching and 
negligible differences in baseline differences between groups. 
BMI = body mass index; RDCI = Rheumatic Disease Comorbidity Index; ACE inhibitors = angiotensin 
converting enzyme inhibitors; ARBs = angiotensin receptor blockers; CCBs = calcium channel blockers; 
NSAIDs = non-steroidal anti-inflammatory drugs (NSAIDs); eGFR = estimated glomerular filtration rate 











(n =  6,065) 
Dose Escalators 
(n =  6,065) 
 Non-Escalators† 
(n =  6,065) 
Dose Escalators 
(n =  6,065) 
≤ 100 76% 76%  78% <1% 
> 100 & < 300 19% 19%  18% 38% 
300 5% 5%  4% 51% 
> 300 <1% <1%  <1% 10% 
* Dose represents the average daily dose with allopurinol equivalents used for febuxostat in follow-up calculations.   † A 
small proportion of non-escalators (4%) had their dose decreased during the 2-year follow-up.  
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Table 11  Follow-up Serum Urate (SU) by Group 
 Dose Escalators  
(n =  6,065) 
Non-Escalators 
(n =  6,065) 
SU Tested 91% 77% 
At SU Goal < 6.0 mg/dL* 31% 12% 
Follow-up SU, mean mg/dL 6.9 ± 1.9 7.6 ± 1.7 
Values are percentages and mean ± SD. Only the last value on record for follow-up 
was used if there were multiple. * Calculation includes those missing SU tests. 
Among only those with follow-up testing 34% of dose escalators and 16% of non-







Figure 5  Time to Death for Propensity Matched Dose Escalators and Non-escalators 
The cumulative incidence of (A) all-cause mortality, (B) cardiovascular mortality, (C) cancer mortality during 




Table 12  Assessment of Quality of Care as a Residual Confounder 
 Baseline  Follow-up 








Observability* 100% 100%  94% 91% 
BP < 140/90 mmHg 63% 63%  68% 68% 
Cholesterol < 200 mg/dL 72% 71%  80% 78% 
* Observability at baseline was defined for a 1-year period, but was defined for the full 2-year dose 
escalation period for follow-up. A patient was considered observable for the period if they were observable 
for both 1-year periods. All lab values are the last on record during the 2-year follow-up if more than one was 
available. 




In this study, there was no evidence that current dose escalation practices reduce 
mortality risk, all-cause or cause-specific. ULT dose escalation produced a statistically 
insignificant 4% reduction in all-cause mortality risk as well as non-significant 3% and 
8% reductions in cause-specific mortality of cardiovascular and cancer etiology, 
respectively. The lack of statistical significance was despite this being the largest study 
to date of ULT treatment effects on gout patient mortality.112,113,128  However, I also 
showed that patients receiving ULT dose escalation were not dose escalated to a level 
typically required for proper gout control.38,39 Such clinical inertia, especially among 
those receiving dose escalation, limited my ability to determine the effect of appropriate 
dose escalation on mortality. These results add to the persistent uncertainty regarding 
the role of ULT in reducing mortality risk.107,129 
This study has a number of design strengths that further inform our understanding of 
ULT and mortality risks. First, I successfully linked a large national cohort of gout 
patients to cause-specific mortality data. Previous studies have typically reported all-
cause mortality thus limiting understanding about the relative impact of therapy on 
causes of mortality such as cardiovascular disease or cancer.112,113 While most studies 
have focused on the potential cardiovascular benefits of ULTs that may lead to reduced 
mortality,129 there is a potential that reducing hyperuricemia may also have effects on 
cancer mortality.107 While neither were statistically significant in this study, the point 
estimate for reductions in cancer mortality was stronger than reductions for 
cardiovascular mortality. Few conclusions should be drawn from these findings other 
than to emphasize that until a more definitive link is determined, assertions regarding 




This study employs a new-user, active-comparator design novel among studies of 
ULT treatment associations with mortality among gout and hyperuricemic patients. This 
approach is particularly robust as it better reflects treatment decisions and treatment 
recommendations for gout and hyperuricemia than study designs using comparisons 
against non-initiator groups (patient never treated with allopurinol). Comparing to 
patients not initiated on therapy is likely a comparison against a heterogeneous group.130 
Specifically, not all gout patients are recommended for ULT, such as those experiencing 
infrequent gout attacks and lacking tophi or evidence of gout-related joint damage.38,49 
Additionally, patients with asymptomatic hyperuricemia are not recommended for ULT 
initiation.38,49  These two groups comprise a low-risk subpopulation of non-initiators. The 
non-initiator group likely also contains a high-risk population of patients, potentially near 
death, for whom prescribers are less likely to initiate a new medication.130 Studies in 
other diseases have termed this the risk-treatment mismatch or paradox.131,132  This 
study mitigates this potential bias by comparing two groups both initiating ULT therapy. 
The similarity of the dose escalator and non-escalator groups is reflected in the 
unmatched baseline characteristic comparisons in Table 9. This study further balanced 
residual differences between groups through a rigorous propensity score 
method.124,125,133 Together, these methods likely led to a less biased estimate of 
treatment effect. 
Here and elsewhere, I have demonstrated that clinical inertia, or the lack of 
increasing treatment intensity when indicated,84 is common in gout management even 
among those receiving initial dose escalation.32 In this study, only 30% of dose 
escalation patients completed the 2-year follow-up period at SU goal. It is possible that 
the clinical inertia observed in this study greatly limited my ability to determine ULT dose 
effects on mortality risk reduction. The potential that such under-dosing limited my 
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findings is consistent with at least one study showing that increases in forearm blood 
flow, a measure of endothelial function, were significantly greater for patients 
randomized to 600 mg/day allopurinol doses than for those assigned to 300 mg/day or a 
placebo.111 Additionally, if the mortality reduction hypothesized to be attributable to ULT 
is associated with reductions in cumulative systemic inflammation from gout attacks,134 
then dosing practices reported in this study are unlikely to decrease such inflammation. 
International guidelines, supported by evidence-based studies, recognize that dose 
escalation until SU is below 6.0 mg/dL is typically required for long-term reduction in 
gout attacks.38,49 Without SU goal achievement, allopurinol initiation may only serve to 
transiently increase systemic inflammation associated with treatment initiation attacks 
while not serving to significantly reduce long-term attack risk.85-87 
In the place of ULT dose escalation, I could have considered the effect of SU goal 
attainment or SU change on mortality risk similar to a recent study.128 That approach 
would have directly investigated one of the hypothesized causal links, SU concentration, 
between ULT and mortality reduction.107,129 However, I chose to focus on dose 
escalation for a number of reasons. First, the approach frames the issue as an RCT 
would by comparing the effect of treatment strategies. Second, investigating dose effects 
more broadly reflects the many hypothesized mechanisms through which allopurinol or 
febuxostat may reduce mortality. Specifically, studies indicate that allopurinol may 
improve endothelial function through its inhibition of xanthine oxidase and corresponding 
reduction in reactive oxygen species rather than its urate lowering effect.111,129 Third, 
there exists a significant deficit in periodic SU evaluation among observational cohorts 
creating a potentially insurmountable missing data problem. Specifically, estimates of 
follow-up SU testing range from 15-30% at 6 months to 50% at 4 years.48 Such 
infrequent testing and likely baseline differences between those with follow-up SU 
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testing versus those without would have made even the best imputation techniques 
inadequate. Thus, my decision to investigate dosing strategies reflects my belief that it 
better reflects provider treatment choices, the totality of hypothesized causal effects, and 
the limitations of available data. 
Despite the many strengths of this study, interpretation must account for its 
limitations. As previously noted, my ability to fully understand the dose effects of ULT 
was limited by the clinical inertia observed in practice. This study is observational in 
nature. While the new-user, active-comparator design and use of propensity matching 
likely mitigated potential confounding by many measured and unmeasured risk factors, I 
cannot eliminate the potential for residual unmeasured confounding. To specifically 
address gout severity as a residual unmeasured confounder, I included baseline SU 
level, rheumatologist care and number gout diagnostic codes on record as proxies for 
severity. While these methods were improvements over past studies, current medical 
records are limited in their ability to determine gout severity with no validated and 
systematically documented measures that would fulfill this need. Finally, the population 
largely reflects the patient population typically being treated with ULT for gout. However, 
females comprised less than 1% of the population limiting external validity of the results 
for females.  
In conclusion, I found no association between ULT dose escalation and reduced 
mortality. The findings were likely limited by suboptimal ULT dosing observed in practice 
even among dose escalators. While I hoped that this study would add to the evidence 
that appropriate dose escalation has significant benefits for gout patients, clinical inertia 
during appropriate dose escalation is so prevalent that I cannot make a definitive 
assessment. Interventions to overcome clinical inertia in ULT dose escalation may be 
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needed before understanding about dose effects can be made, including the potential 
benefits for mortality. 
Chapter 5: Discussion 
5.1 Summary 
Gout is the most common form of inflammatory arthritis, but it is also considered one 
of the most treatable. In this dissertation, I have applied the patient and provider portion 
of the Chronic Care Model (CCM) framework to draw further insight into modifiable 
barriers to optimal outcomes in gout. Importantly, this work builds on prior studies that 
identified deficits related to quality indicators, safe prescribing or patient adherence to 
therapy by assessing their association with optimal outcomes in an observational setting. 
These findings build a foundation for future work to target important modifiable factors 
identified here. 
Patients’ engagement in their own care is increasingly recognized as a critical 
pathway toward improved outcomes.14 In this dissertation, I demonstrated that gout 
patients may have a deficit in treatment goal knowledge relative to other knowledge 
about gout. Only 14% of patients knew their serum urate (SU) goal. Yet, over 70% 
answered at least 4 out of the other 5 gout knowledge questions correctly indicating an 
otherwise good understanding of their disease. This discrepancy between knowledge of 
gout as a disease and knowledge of a critical treatment goal raises the potential that 
goal setting is underutilized in gout care. Literature on goal setting in health suggests 
that it may be an important aspect of obtaining optimal outcomes for chronic 
diseases.59,74,75 More broadly, knowledge of goals and goal-setting processes are 
highlighted in numerous behavior change and theoretical models including CCM.10,11,58 
In the following section, I identify initiatives where SU goal is currently being promoted 
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and demonstrate the many ways that a goal-setting framework can be incorporated into 
comprehensive approaches to CCM-based improvement initiatives. 
Recently, more emphasis has been placed on a collaborative patient-provider 
approach to achieving optimal outcomes in chronic disease.59,76,135 In this dissertation, I 
demonstrated that current practices in gout management may benefit from greater use 
of a collaborative approach. Specifically, both patients’ adherence to urate lowering 
therapy (ULT) and providers’ dosing practices were strongly associated with SU goal 
attainment. For provider dosing practices, dose escalation and high starting dose were 
significantly associated with SU goal attainment, but high starting dose was also 
associated with worse SU goal attainment through its negative effects on ULT 
adherence. The effect of a provider’s choice for starting ULT dose on patient’s ULT 
adherence illustrates a specific area of potential impact for a more collaborative 
approach. If providers start on lower ULT doses and work with patients to overcome 
initiation attacks and other challenges that arise when starting a new ULT, patients 
would likely achieve better outcomes. Demonstration of the interrelation between patient 
and provider behaviors is not limited to my findings. In diabetes, studies show that low 
patient medication adherence is associated with clinical inertia in potentially appropriate 
treatment intensification.136,137 This is a potentially intuitive finding. Providers may 
recognize that some patients are nonadherent creating uncertainty regarding the 
appropriateness of treatment intensification. Thus, if patients remain nonadherent, then 
interventions focusing strictly on dose escalation practices may be incongruent with the 
realities of practice and thus fail to impact outcomes. The interrelated nature of patient 
and provider behaviors increases the need for multi-faceted interventions. I explore 
potential components of multifaceted approaches in the following section on future work. 
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The difficulty of demonstrating associations of certain modifiable patient and provider 
behaviors with long-term outcomes has been a major barrier in developing an evidence-
based approach to improving patient outcomes in practice.138 In Chapter 4, I developed 
a promising and methodologically rigorous approach to understanding the effect of ULT 
dose escalation on mortality outcomes in gout. I used a new-user, active-comparator 
design and propensity score matching approach to investigate whether a ULT dose 
escalation strategy was associated with decreased mortality relative to a static dose 
strategy. While I found no difference in mortality outcomes between the two dosing 
strategies, conclusions were limited due to pervasive clinical inertia even among dose 
escalators. With only 30% of patients achieving SU goal and only 10% being escalated 
above 300 mg/day of allopurinol, I was forced to conclude that current dose escalation 
efforts are insufficient to determine the effect of appropriate dose escalation. While 
limiting for understanding associations of ULT with mortality outcomes in gout, the 
findings further emphasize the importance of developing methods to target patient and 
provider factors identified in this dissertation as important for achieving SU goal. 
5.2 Future Work 
Chronic diseases are likely to remain a primary driver of health care utilization for the 
foreseeable future. For this reason, methods for improving patient outcomes in chronic 
disease will need to evolve to address the ever growing demand. Often, the quick and 
easy solution suggested by researchers who identify gaps in quality of care is to provide 
more education to patients and providers, but decades of research indicate that such an 
approach has limited effectiveness.58,139,140 Knowledge, alone, is not sufficient. Instead, 
there is convergence from research in a number of fields, including treatment 
adherence,141 clinical decision support,142 and dissemination and implementation 
research138 indicating that successful interventions are most often multi-level (e.g. target 
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individuals, systems and/or organizations) and multi-faceted (e.g. use two or more 
methods flexibly for accomplishing the same outcome). The CCM, supplemented by 
other work, provides a foundation for developing multi-level, multi-faceted approaches 
for improving quality and patient outcomes in gout care. 
First, there is a critical need for development of clinical information systems that 
better reflect the diagnostic process, shared-decision making, clinical context, and 
uncertainty. For the studies reported here, I used a common medical coding system and 
medication prescribing to identify gout patients for whom treatment was initiated. This 
approach is commonly used in health services research and beyond, but it has 
limitations. Medical coding, developed primarily for billing purposes, does not equate to 
disease presence. For this reason, there are efforts to develop ‘computable phenotypes’ 
for diseases with the idea that differing combinations of diagnostic codes, timing of 
codes, and other factors can improve the sensitivity and specificity for disease 
identification.143 Well-documented and validated computable phenotypes will improve 
identification, but still lack the functional meaning that would facilitate improvements in 
quality of care. Efforts to improve care based on electronic health records would benefit 
from greater detail about the goal of treatment or lack of treatment to guide 
understanding of expected outcomes. This information could even incorporate shared-
decision making, or the process of patients and providers reviewing evidence to 
collaboratively determine the best course of action for a particular patient.144 For 
instance, in gout there is little debate that health care providers should suggest long-
term ULT for patients severely affected by gout, but for patients with infrequent attacks 
who do not want to take a daily medication there is uncertainty about the benefits of 
long-term therapy. 38 Shared-decision making may be particularly useful in cases where 
uncertainty is highest. Similarly, the A1c treatment goal for diabetic patients can vary 
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depending on their risk for developing dangerous hypoglycemic episodes creating 
uncertainty in the optimal goal.145 Clinical information systems should be able to reflect 
therapeutic goals that develop over time and respond to patients’ changing conditions. 
Understanding the goal of treatment and the input of patients could deepen 
understanding of quality beyond the one-size-fits-all approach often imposed in research 
studies due to current record-keeping limitations. Indeed, some suggest that evidence-
based medicine loses significance without inclusion of patient preferences.142,144 Until 
clinical information systems better track varied circumstances of treatment and goals, 
our ability to understand quality using these systems will be limited to sometimes overly 
generalized assumptions. 
 Clinical decision support is an approach addressed by CCM that has enormous 
potential to assist health care providers in overcoming barriers to outcomes identified in 
this dissertation. Clinical decision support relies on the idea that a health care provider 
working in partnership with a well-designed, user-centered information resource will 
perform better than a provider on their own.146 A potential approach in gout and other 
chronic diseases would be to create disease dashboards147,148 that would simultaneously 
allow the provider to review a patient’s disease-specific history and nudge them to make 
decisions consistent with the patient and current evidence-based recommendations.  For 
instance, a gout dashboard could display a patient’s history of gout attacks, a graph of 
their historical SU levels with relevant ULT doses, and one-click ordering for SU testing 
or ULT. The system could even nudge providers by making the default option for ULT a 
dose escalation if the patient is below SU goal or a reorder (static dose) if the patient is 
at SU goal. Since chart review is where providers spend a large share of their time when 
using electronic health records,149 convenient organization of disease information and 
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ordering could simultaneously improve efficiency and help overcome clinical inertia in 
dosing practices. 
Another opportunity identified by CCM is delivery system design. Bodenheimer and 
colleagues suggest that the ‘tyranny of the urgent’ during clinic visits overwhelms the 
periodic steps required for optimal chronic disease management.14 A potential method of 
addressing this is to allow the primary health care provider to initiate treatment strategies 
that are efficiently operationalized by a health care team and potentially facilitated by 
technology. Interestingly, this approach is currently being studied as part of a pragmatic 
randomized trial for gout treatment within a large integrated health system.150 In the trial, 
gout patients are identified through electronic medical records shortly after initiating 
allopurinol. An ambulatory care pharmacist and an automated calling system are then 
used to provide protocolized care promoting SU goal attainment. Consistent with 
findings in this dissertation, the protocol emphasizes improving medication adherence 
among patients who report poor ULT adherence and then dose escalating patients who 
fail to achieve SU goal despite being adherent. This is but one approach to system 
redesign that could improve outcomes by separating the predictable sequences of care 
required to achieve optimal chronic disease outcomes from the primary care provider’s 
important role in identifying disease, initiating therapy strategies, and addressing critical 
issues that arise overtime in care. 
The CCM suggests that for chronic conditions, self-management support should 
involve “collaboratively helping patients and their families acquire skills and confidence 
to manage their chronic illness, providing self-management tools…, and routinely 
assessing problems and accomplishments.”14 The level of self-management support 
changes in direct proportion to the pervasiveness of the disease and treatment impact 
on the patient’s day-to-day life. For instance, intensive self-management programs were 
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developed for rheumatoid arthritis patients during the 1990’s when the disease was often 
crippling despite therapy.15 Fortunately for most gout patients, self-management is 
limited to eating a good diet, exercising, and properly using medications. However, as I 
demonstrated in Chapter 2, even these self-management activities can pose substantial 
challenges. When a patient is initiated on ULT, they may experience initiation attacks 
causing them to discontinue therapy without notifying their health care provider. 
Appropriate response to gout attacks is a critical self-management skill for gout patients 
that may not be required for months after first learning from the doctor what to do, if they 
are informed at all. In addition to the finding that patients may be inappropriately 
discontinuing therapy, one study suggests that patients who visit their health care 
provider during an attack may actually be more likely to use therapy inappropriately 
following their visit.151 Recognizing the limitations of early in-office patient education, 
these findings suggest that direct-to-patient resources providing timely and patient-
centered information may have a role in optimizing self-management. For instance, a 
smartphone app could allow patients to review long-term management152 and also push 
time-sensitive information to patients. In gout, patients could be given access to track 
progress toward SU goal over time, which may provide the conceptual link between their 
medication use and health that is necessary to promote adherence. Beyond tracking 
treatment progress, smart phones could use predictive analytics to identify when a 
patient is likely to be having a gout attack and provide the patient with in-the-moment 
instructions for medication use. These approaches represent important opportunities to 
develop better self-management among patients and could translate into improved long-
term outcomes.  
In addition to the above 4 areas, CCM identifies two broader areas where targeted 
efforts may improve outcomes: community resources and policies and health care 
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organization. Communities can significantly impact patients’ chronic disease outcomes 
through the availability of healthful food,153 safe outdoor exercise areas,154 and social 
support groups.155,156 In gout, community norms surrounding each of these has the 
potential to reduce the number of people developing gout as well as reducing 
consumption of common triggers of gout attacks (e.g. purine-rich meats, high-fructose 
drinks, and beer).157 In addition to communities, the organization of health care can have 
an outsized impact on chronic disease outcomes.158-160 For instance, government and 
health care businesses can promote or discourage certain care practices through 
incentives.161,162 It is now widely recognized that the US health care system payment 
structure primarily incentivizes the volume of health care, such as the number of short 
clinic visits and procedures, more heavily than quality which may require more time 
dedicated to care follow-up and behavioral change approaches.163 More recently, efforts 
have been aimed at altering incentives to better reflect the type of chronic care that 
patients like those with gout require. For instance, payment models are being developed 
that may make it more financially feasible to use clinic time to coordinate chronic 
care.164,165 While the community and health care organization elements of the CCM are 
sometimes more difficult to target in research, their effects can be far reaching and 
should not be over looked.  
5.3 Conclusion 
Improving patient outcomes in chronic disease is of critical importance to the future 
of health care. Gout, affecting 4% of the US population, is a highly treatable chronic 
disease from which patients experience unnecessarily suboptimal outcomes. In this 
dissertation, I demonstrate how interrelated patient and provider factors affect patient 
outcomes in gout.  Importantly, the factors, including low knowledge of SU goal, low 
patient ULT adherence and suboptimal ULT dosing practices by providers, are all readily 
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modifiable. Historically, efforts to improve patient and provider behaviors have focused 
on education and outreach, but future interventions will likely find greater success 
addressing the broad care context outlined in the CCM to target these interrelated, 
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Appendix A: Questionnaire 
Gout Quality Improvement Project
Date you completed this questionnaire:
 FOR OFFICE USE ONLY
/ /






1. You will need a blue or black pen that won't bleed through the paper.
Please do not use pencil or red ink.
2 . You will see a lot of small squares like this:
3. You will also see some scales like the one below. You will need to make a mark in the box that
best corresponds to your answer. These scales are usually 0-10. Read carefully to determine what
the question is asking. In this example, the box marked with an X represents a person having a
great deal of pain.
These squares should be marked with an X like this:
Be sure to make your X inside the box, and fairly heavy, so the computer can read it.
NO PAIN SEVERE PAIN
100
Please do NOT write your name or identifying information on this questionnaire.
By filling out this questionnaire, you are consenting to be in the study and have
your medical records reviewed.
27421
Dissertation Appendix A: Questionnaire
Page 2
Background
2. Does someone else, such as a family member, help you take your medications? Yes No
3. Do any non-VA, private providers manage your gout? Yes No
Treatment Plan
1. How confident are you that you and your doctor have discussed the medication options available






2. How confident are you that you and your doctor have discussed lifestyle and diet changes that may
    help control your gout?
3. How confident are you that you could summarize the treatment plan you and your doctor have chosen
    to control your gout?
4. How confident are you that you can do all the tasks in the treatment plan?
The following questions are meant to gather background information about you.
4. Do you receive any prescription medications from a pharmacy other than
    the VA pharmacy?
1. How old were you when you had your first gout attack?                  years old
Yes No
The following are questions about the treatment plan you and your doctor have decided on




















Personal Views about Health
Strongly
Disagree  Disagree Agree
Strongly
Agree
1. When all is said and done, I am the person who is
    responsible for taking care of my health.
2. Taking an active role in my own health care is the most
     important thing that affects my health.
3. I am confident I can help prevent or reduce problems
    associated with my health.
4. I know what each of my prescribed medications do.
5. I am confident that I can tell whether I need to go to the
    doctor or whether I can take care of a health problem myself.
6. I am confident that I can tell a doctor concerns I have even
    when he or she does not ask.
7. I am confident that I can follow through on medical
    treatments I may need to do at home.
8. I understand my health problems and what causes them.
9. I know what treatments are available for my health problems.
10. I have been able to maintain (keep up with) lifestyle
      changes, like eating right or exercising.
11. I know how to prevent problems with my health.
12. I am confident I can figure out solutions when new
      problems arise with my health.
13. I am confident that I can maintain lifestyle changes,
      like eating right and exercising, even during times of stress.
Below are statements that people sometimes make when they talk about their health. Place an X in a box
to the right of each statement according to how much you agree or disagree with it. When answering
please consider your health generally. Your answers should be true for you and not just what you think
others want you to say.
If the statement does not apply to you,







3. How many acute gouty arthritis flares or attacks have you had in the past 6 months?
0 1 2 3 4 5  more than 6
Page 4
The following questions ask you to share your views about your health and how gout
affects it.
Place an X in the box that best describes how you are doing.
2. Considering ALL THE WAYS THAT GOUT AFFECTS YOU, rate how you are doing on the
    following scale.











The following questions ask for your views about anti-gout medication. Please place an X in the
box to show how much you agree or disagree with each of the following statements.
1.  My anti-gout medication works for me.
2. My anti-gout medication makes me feel worse.
1. I took all doses of my anti-gout medication.
2. I missed or skipped at least one dose of my anti-gout medication.
3. I was not able to take all of my anti-gout medication.
Strongly disagree Disagree Neutral Agree Strongly agree
Strongly disagree Disagree Neutral Agree Strongly agree
Over the past 7 days:
Strongly disagree Disagree Neutral Agree Strongly agree
Strongly disagree Disagree Neutral Agree Strongly agree





I have no problems walking
I have slight problems walking
I have moderate problems walking
I have severe problems walking
I am unable to walk
I have no problems washing or dressing myself
I have slight problems washing or dressing myself
I have moderate problems washing or dressing myself
I have severe problems washing or dressing myself
I am unable to wash or dress myself
I have no problems doing my usual activities
I have slight problems doing my usual activities
I have moderate problems doing my usual activities
I have severe problems doing my usual activities
I am unable to do my usual activities
I have no pain or discomfort
I have slight pain or discomfort
I have moderate pain or discomfort
I have severe pain or discomfort
I have extreme pain or discomfort
I am not anxious or depressed
I am slightly anxious or depressed
I am moderately anxious or depressed
I am severely anxious or depressed
I am extremely anxious or depressed
For each question below, place an X in the one box that best describes your overall health today.
MOBILITY
SELF-CARE
USUAL ACTIVITIES (e.g. work, cooking,






6. If you are taking a drug to lower your blood uric acid levels, how long do you need to take this drug?
One month One year Two years Forever Don't know
Gout Knowledge
1. What causes gout?
Too little calcium Too much uric acid An infection Diabetes Don't know
3. How do you know if you have a gout attack?
You have a painful swollen joint You have a change in your blood tests
Your skin gets red and itchy You have a lump on your ear
Don't know
4. Lowering your uric acid can help prevent future gout attacks. Which of these drugs can lower your
    blood uric acid?
Allopurinol NSAIDs like ibuprofen, naproxen and indomethacin
Prednisone Colchicine Don't know
5. What is the ideal blood uric acid level to aim for when treating gout?
    Blood uric acid levels are measured in mg/dL.
Lower than 10 Lower than 8 Lower than 6 Lower than 2 Don't know
The following questions ask you to share what you know about gout. Since we are hoping to determine
if certain knowledge is useful for you, it is important that you answer these questions without any help.
Please select only 1 answer for each question.
2. What causes gout attacks? Infection in the joint Allopurinol in the blood
Crystals in the joint Calcium in the blood Don't know
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17+
- - - - - - - - - - - -Grade School - - - - - - - - -
- - - -- - -
 - - - -High School- - - - - - - - - - - -College- - - - - - - - - - - - -
- - - - - -
1. How many years of school have you completed?  Please X the box to the left of the number
    of years of school you have had.
2. Please tell us your ethnic background:
White, not of hispanic origin
Black, not of hispanic origin
Asian or Pacific Islander
Hispanic
American Indian or Alaska Native
Other
3. Current marital






Remarried after death of spouse
Remarried after divorce
(check one)
Thank you for completing the survey. Please place it into the envelope provided and return
it by US mail. The envelope has already been addressed and stamped for return so there is
no cost for you!
10000000
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